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ABSTRACT

Wanjala, Irene Werengekha. Ph.D. The University of Memphis. December, 2010.
Characterization of the structure and function of nucleotide
pyrophosphatase/phosphodiesterase-7
Major Professors: Daniel L. Baker and Abby L. Parrill

Nucleotide pyrophosphatase/phosphodiesterase (NPP) 7, also known as alkaline
sphingomyelinase (Alk-SMase) is a membrane-anchored ectoenzyme initially discovered
in the rat intestinal tract in 1969. It is the most recently identified NPP isoform. The
family currently consists of seven members, NPP1-7, numbered according to the order in
which they were first associated with the family. NPP enzymes hydrolyze a wide range of
substrates. NPP1and NPP3 are nucleotide pyrophosphatases that cleave inorganic
phosphate from nucleotides and their derivatives. In contrast, NPP2, NPP6 and NPP7 are
phosphodiesterases that hydrolyze phosphodiester bonds in lysolipids and their
derivatives. NPP4 and NPP5 are yet to be characterized in terms of substrate preference
and biological function. Numerous lysolipid derivatives have been shown to be
hydrolyzed by NPP2 and NPP6 but only three main lysolipid substrates have been
previously reported for NPP7. One of the goals of this work was to characterize the
substrate preference of NPP7 through more exhaustive kinetic means. Our results show
that NPP7, like NPP2 and NPP6, hydrolyzes numerous choline-containing substrates
including glycerolipids, lysophosphatidylcholine, platelet activating factor, lyso platelet
activating factor and the sphingolipids, sphingomyelin and sphingosylphosphorylcholine.
A synthetic small molecule, para-nitrophenyl phosphocholine was also identified as a
substrate for NPP7. Like NPP6, NPP7 hydrolyzed all identified substrates with a
v

lysophospholipase C activity and like NPP2, NPP7 preferred larger lipid substrates to the
smaller non-lipid substrates tested.
Most hydrolytic activities of NPP isoforms lead to formation of bioactive lipids
that affect numerous physiological and pathological processes. This, coupled with their
extracellular activity, makes them attractive targets for therapeutic intervention. A major
bottleneck to their utilization as therapeutic targets is that very little is known about their
structure and function. Although NPP enzymes hydrolyze a wide range of substrates, and
sometimes share a common substrate, they exhibit different substrate preference profiles,
the factors producing these substrate profiles have not been previously investigated. Our
second goal was therefore to employ computational modeling as a rational tool to guide
experimental procedures in exploring NPP7 substrate specificity determinants. Our
modeling results suggest the presence of a common binding pocket for the different
substrate groups of NPP7and presence of essential non covalent interactions between the
substrate and specific amino acid residues.
Like alkaline phosphatases, NPP isoforms require two divalent metal cations
within their catalytic core and are inactivated when the metals are removed. The amino
acid residues that coordinate these metal cations are conserved within NPP and AP
isoforms. However, the specific endogenous divalent metal in individual NPP isofomrs is
not yet known. It still remains an open question as to the specific role of these divalent
metal cations in enzyme activity. Our third goal was therefore to explore the role played
by divalent metal cations during the NPP7 catalytic cycle. Our results indicate that the
secondary structure of NPP7 is not altered in presence or absence of divalent metal
cations. However, its catalytic function is eliminated with prolonged exposure to
vi

sufficient amounts of metal chelators. The current work significantly advances our
understanding of NPP7 in terms of preferred substrates, the amino acid determinants that
underlie these preferences and the role of divalent catalytic site metal ion in the structure
and function of the enzyme.
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PREFACE

This dissertation presents a detailed description of our efforts to better understand
the structure and function of nucleotide pyrophosphatase/ phosphodiesterase-7 (NPP7).
NPP7 was discovered more than 40 years ago and has been associated with a wide range
of biological processes. Despite its relatively long history and importance, its structure
and function are not yet well understood. NPP7 was choosen as the focus of this work, in
part, because it is one of the smaller isoforms within the NPP family and could be used as
a model for the larger isoforms that are more difficult to isolate and characterize.
Computational molecular modeling, molecular biology and biochemical methods
have been used to study the structure and function of NPP7. The work in chapter 3 is an
extensive survey of NPP7 substrates in which three new substrates were identified for the
enzyme. This work is submitted to the Journal of Lipid Research. Chapter 4 is a
discussion of the use of computational homology modeling to identify substrate
recognition determinants for NPP7 and the experimental validation of these results by
mutagenesis and biochemical analyses. This work is submitted to the Journal of
Molecular Pharmacology. Chapter 5 presents work on the role of divalent metal cations
in NPP7 and was performed as a comparative survey with NPP2 and NPP6. The work is
to be submitted as an equally authored paper by Dr. Truc Chi Pham, Irene W. Wanjala
and Angela L. Howard to Biochemical Journal. Only work specific to NPP7 is presented
in chapter 5 of this dissertation. To help maintain continuity, chapters 1 (introduction), 2
(molecular biological strategies and procedures) and 5 (metal ion effects) are also
formatted following Journal of Lipid Research guidelines.
viii
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CHAPTER 1

INTRODUCTION

1.1

NPP7 history
Nucleotide pyrophosphatase/ phosphodiesterase 7 is also known as alkaline

sphingomyelinase (alk-Smase) (1-5) and was initially discovered in 1969 by Swedish
scientist, Åke Nilsson (6). However, it remained relatively obscure for thirty years due
to a lack of understanding of its biological relevance. Initially, sphingomyelin (7) was
the only known substrate and no further biological significance was associated with SM
hydrolysis (8). However, in the late 1990s, it was shown that sphingomyelin
metabolism leads to the formation of both proliferative messengers such as
lysosphingomyelin, sphingosine-1-phosphate, and ceramide phosphate and antiproliferative messengers such as ceramide and sphingosine (9). This revelation led to
rejuvenated efforts toward identifying the biological significance of this enzyme. Initial
investigations established that although NPP7 hydrolyzed sphingomyelin (SM) at
alkaline pH, hence its name alkaline sphingomyelinase, it has no structural similarity
with known acid and neutral sphingomyelinases (3). In 1997, alk-SMase was shown to
have structural and functional similarity with the NPP subfamily of alkaline
phosphatase enzymes (10).

1

1.2

The NPP isoforms
The NPP family currently consists of seven members named NPP1-7 in the order

in which they were first associated with the family (1). All isoforms, with the exception
of NPP2, are membrane-anchored ectoenzymes classified as either type I or type II
membrane proteins depending on their orientation relative to the cell membrane (1).
NPP1 and 3 are type II (extracellular C-terminus) while NPP4-7 are type I (extracellular
N-terminus) transmembrane proteins. NPP2 is the only secreted member of the family
(11). All seven isoforms have structural and functional similarities described in the
following sections.

1.3

Structural similarities among NPP isoforms

1.3.1

Conserved extracellular catalytic domains
All NPP enzymes have a modular structure with a conserved catalytic domain of

nearly 400 amino acid residues as shown in Fig. 1.1. The different human isoforms
exhibit 24-60% overall conserved amino acid identity (1). In addition to the conserved
catalytic domains, NPP4, NPP5, NPP6 and NPP7 also contain a putative N-terminal
signal peptide and a C-terminal transmembrane domain. Their C-termini traverse the cell
membrane while their catalytic domains face the extracellular space (1, 12). Functionally
active, truncated forms of NPP6 (5) and NPP7 (13) that lack this C-terminal membrane
anchor, termed Ex-constructs, have been described that are secreted by mammalian cells.
NPP1 and NPP3 have N-termini that traverse the cell membrane. Despite this reversed
orientation, the catalytic domains of these isoforms also face the extracellular space (12).

2

The remaining isoform, NPP2, is synthesized as a pre-pro-enzyme that is secreted in
active form after proteolytic processing (14).

1.3.2

Nuclease-like domains and somatomedin B-like domains
The larger NPP isoforms, NPP1, NPP2 and NPP3, have nuclease-like domains on

the C-terminal side of their catalytic domains. These nuclease-like domains are similar in
primary amino acid sequence to DNA and RNA-nonspecific endonucleases but lack this
catalytic capacity, and they lack the residues required for endonuclease activity (1).
NPP1-3 also contain two somatomedin B-like domains that were initially thought to be
involved in homodimerization (1). However, the role of the somatomedin B-like
domains in NPP isoforms remains unknown as it has now been shown that none of the
NPP isoforms form dimers (15).

3

Modular structure

Isoform
NPP1

H2N

Orientation

Catalytic domain

Nuclease-like domain

COOH

Type II

Catalytic domain

Nuclease-like domain

COOH

Secreted

Catalytic domain

Nuclease-like domain

COOH

Type II

T

NPP2

H2N
T

NPP3

H2N
T

NPP4

NPP5

H2N

Catalytic domain

H2N

Catalytic domain

Type I
COOH

T

NPP6

NPP7

H2N
H2N

Type I

COOH

T

Type I

COOH

Catalytic domain
S

Type I

COOH

Catalytic domain
T

Transmembrane domain/signal anchor
Signal peptide sequence

Somatomedin B-like domain
T

Catalytic residue

Fig. 1.1. The domain structure of the known NPP isoforms. The seven NPP isoforms are
arranged in the order of their initial association with the NPP family. (1)

1.3.3

Conserved catalytic and metal-binding sites
All seven NPP isoforms contain a single conserved nucleophilic alcohol-

containing catalytic residue (12). In NPP6 this is a serine (5) while all other NPP family
members contain a threonine (12). In close proximity to the single catalytic residue are
two divalent metal cations that are important in catalytic function. The residues
coordinating these divalent metals are conserved in identity and spatial arrangement as
those of other sulfo- and phospho-coordinating metalloenzymes such as alkaline
phosphatases (12). However, the metal identity and requirement for each NPP enzyme
are still not known. The NPPs are believed to have a similar catalytic mechanism to that
4

of the closely related alkaline phosphatases (APs) and amino acid residues that coordinate
the two metal cations within the catalytic site are conserved in both families of enzymes
(12). Sequence comparisons indicate that for all NPPs, metal 1 is coordinated by two
histidines and one aspartate while metal 2 is coordinated by two aspartates and one
histidine.

1.4

Functional similarities among NPP isoforms

1.4.1

The catalytic cycle of NPP isoforms
The catalytic mechanism for NPP enzymes has been proposed based on that of the

extensively studied and closely related alkaline phosphatases (1, 12). The NPP7 catalytic
cycle occurs in several steps as shown in Fig. 1.2. In the first step, the phosphate group of
the incoming substrate is attacked by a metal-activated hydroxyl group of the catalytic
residue, threonine75 (T75) in NPP7. This leads to the formation of a phosphodiester
linkage with the substrate phosphate resulting in a metal stabilized enzyme-substrate
complex. In the second catalytic step, one of the divalent metal cations activates a water
molecule by lowering its pKa and facilitates a nucleophilic attack on the phosphate atom
of the intermediate. This leads to regeneration of the free enzyme with the release of
phosphorylcholine, the second catalytic product (16).

5

Fig. 1.2. NPP7 catalytic cycle. The metal activated OH of T75 attacks the phosphate group
of substrate (SM) in the first step. A stabilized covalent phosphorylated enzyme intermediate
is formed. A metal activated water molecule attacks the phosphate group leading to release
of product generating free enzyme in the second step. M1 and M2 are divalent metal cations
present in the active site of all NPP enzymes (2).

1.4.2

NPP substrate specificity and preferences
NPP enzymes are classified as pyrophosphatases or phosphodiesterases depending

on the substrates they hydrolyze. NPP1-3 are pyrophosphatases that cleave inorganic
phosphates from nucleotides and their derivatives (17). In contrast NPP2, NPP6 and
NPP7 are phosphodiesterases that hydrolyze phosphodiester bonds in lipids and their
6

derivatives (4, 5). NPP4 and NPP5 are yet to be characterized in terms of substrates and
types of activity. NPP2 is the only one of the seven NPP isoforms that is known to
possess both pyrophosphatase and phosphodiesterase activities (1). As a
phosphodiesterase it exhibits lysophospholipase D (LPLD) activity, in contrast to NPP6
and NPP7 both of which exhibit lysophospholipase C (LPLC) activity. Fig. 1.3 illustrates
the two types of activity using a lysophosphatidylcholine (LPC) as an example substrate.
Beside these specific activities, NPP isoforms also exhibit differing substrate preference
profiles but it is unclear what determines these well-defined characteristics. (12, 18).

1.4.3

Biological Significance of NPP Isoforms

Fig. 1.3. LPLC versus LPLD hydrolysis of LPC. NPP7 generates monoacylglycerol
(MAG) and a phosphocholine via LPLC activity while NPP2 generates LPA and choline
via LPLD activity.

7

1.4.3

Biological significance of NPP isoforms
Hydrolytic activities of the NPP enzymes affect a very diverse variety of

biological processes as is summarized in Table 1.1. Hydrolysis of several of their
substrates (especially lipids) generates messengers that mediate numerous signaling
pathways to elicit these biological affects (7, 19, 20).

Table 1.1. Summary of the properties of NPP isoforms
Isoform

Other names

Preferred
substrate(s)

Enzymatic
activity

Biological significance

NPP1

MAFP, NPPase,
NPPγ, NTPPPH,
PC-1

Nucleotides and
derivatives

Nucleotide
Pyrophospha
tase

Bone mineralization
soft tissue calcification
insulin signaling

NPP2

Autotaxin,
lysoPLD, NPPα,
PD-1α

Nucleotides L
lysophospholipids and
derivatives

Nucleotide
pyrophospha
tase and
lysophospho
-lipase D

Normal development
Carcinogenesis
Cardiovascular disease
Neuropathic pain
Obesity, among others

NPP3

B10, CD203c,
gp130RB13-6,
NPPβ, PD-1β

Nucleotides
derivatives

Nucleotide
Pyrophospha
tase

Allergy sensitivity
glial cell differentiation

NPP4

N/A

Unknown

Unknown

Unknown

NPP5

N/A

Unknown

Unknown

Unknown

Choline containing
lysophospho-lipids

Choline
Specific
Lysphospholipase C

Renal Choline
reabsorption

Choline containing
lysophospholipids

Choline
specific
lysphospholipase C

Gastrointestinal
Maturation,
Cholesterol absorption,
Anticancer effects

NPP6

N/A

NPP7

Alkaline
sphingomyelinase
(Alk-SMase)
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1.5

Current studies on the characterization of NPP7
The biological activity of NPP7 warrants further study to better understand its

function. Likewise, understanding NPP7 structure and function will, by analogy, help
understand NPP2 which is an anticancer target. In the current study, we describe the use
of a combination of biochemical and computational methods to significantly expand
knowledge on the structure and function of NPP7. The following three main areas will be
addressed.

1.5.1

Influence of substrate chain length and architecture on NPP7 activity
An extensive investigation of the influence of substrate chain length and

architecture within lysolipids on NPP7 catalytic function is described in Chapter 3.
Through this work we identified two lysolipids; sphingosylphosphorylcholine (SPC) and
lyso platelet activating factor (lyso PAF), and one synthetic small molecule, paranitrophenylphosphocholine (pNPPC), as novel NPP7 substrates. NPP7 activity against
each of these newly identified substrates, as well as the previously known substrates has
been extensively characterized using Michaelis-Menten enzyme kinetics described in
Section 1.5.3.

1.5.2

NPP7 substrate specifying determinants
The use of molecular modeling to investigate substrate recognition by NPP7

and validation of the models using biochemical assays on site-directed mutant proteins is
described in Chapter 4. Analysis of mutant activity and comparison of their efficiency
relative to wild type enzyme was achieved by applying the Michaelis-Menten kinetics for
9

each enzyme against several NPP7 substrates. The mathematical and qualitative basis of
the Michaelis-Menten’s theory of enzyme catalyzed reactions is briefly discussed in
Section 1.5.3. The results obtained show that F275 is essential for recognition of all
choline phosphodiesters by NPP7. In addition, several residues, including E169 and
Y166, were found to play a role in determining NPP7 substrate preferences.

1.5.3

Application of the Michaelis-Menten kinetics to enzyme catalysis
We have applied Michaelis-Menten kinetics to the characterization of the

catalytic behavior of NPP7 and its mutants. As such, a detailed description of the theory
is necessary. The Michaelis-Menten (MM) theory for enzyme kinetics first assumes that
the enzyme, E, and its substrate, S, associate reversibly to form an enzyme-substrate
complex, ES as follows;
k1
E+S

k-1

ES

(1)

This association/dissociation is assumed to be in rapid equilibrium with Ks denoting the
the enzyme : substrate dissociation constant (21). Therefore at equilibrium,
k-1 [ES] = k1[E][S]

(2)

Ks = ([E][S])/[ES] = k-1/ k1

(3)

and

The product, P, is formed in a second step when ES yields the free enzyme plus product
(E + P). The complete reaction equation therefore becomes;
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k1
E +S

k-1

k2
ES

E +P
(4)

After the second step, E is free to interact with another substrate molecule.
Briggs and Haldane refined the interpretations above by assuming that the concentration
of the enzyme-substrate complex, ES, quickly reaches a constant value in such a dynamic
system (22). This means that ES is formed as rapidly from E + S as it disappears through
dissociation to generate E + S and reaction to form E + P. This is the steady-state
assumption where the change in ES concentration with time (t) is zero and is expressed as
d[ES]/dt =0

(5)

With the steady state assumption the rate of formation and breakdown of ES are defined
by rate expressions that involve several rate constants (23). A combination and
simplification of these five expressions summarizes the formation of the ES complex as
follows
[Et][S]
[ES] =
[S]+ {(k1 +k2)/k1}

(6)

The term (k-1 + k2)/k1 is defined as the Michaelis constant, Km and substituting it in
equation (6) gives:
[ES] = [Et][S] / (Km + [S])

(7)

When k2 is rate-limiting, k2 << k-1 and Km reduces to k-1 / k1, which is defined as the
dissociation constant, Kd of the ES complex. Where these conditions hold, K m represents
a measure of the affinity of the enzyme for its substrate in the ES complex. However, this
11

scenario does not hold for most enzymes. In cases where k 2 >> k-1 then Km= k2/k1. In
other cases where k2 and k-1 are comparable Km remains a more complex function of all
three rate constants. In such cases, the Michaelis-Menten equation and the characteristic
behavior of the enzyme still apply but the K m cannot be considered as a simple measure
of substrate affinity.
The Michaelis-Menten kinetics of enzyme catalyzed reactions are also
simplified by the initial velocity assumption where formation of ES from E + P by the
reverse reaction is ignored (24). This is true for the initial velocity for the reaction
immediately after E and S are mixed and [P] is essentially zero. With this simplification,
the initial velocity (Vo) is then described by the breakdown of ES to form product which
is determined by the concentration of the enzyme-substrate complex:
Vo = k2[ES]

(8)

Initial velocity can also be expressed in terms of the Michaelis constant Km as follows:
Vo = k2[Et][S] / (Km + [S])

(9)

The maximal velocity, Vmax, of an enzyme occurs when the enzyme is saturated with
substrate i.e. when [ES] = Et, and can thus be described as k 2[Et]. Therefore equation 9
can also be expressed as:
Vo = Vmax [S] / (Km + [S])

(10)

This is known as the Michaelis-Menten equation, the rate equation for a one-substrate
enzyme–catalyzed reaction. This equation is a statement of the qualitative relationship
between the initial velocity Vo , the maximal velocity Vmax and the substrate concentration
[S], all related through the Michaelis constant K m. Km is expressed in units of
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concentration and is described as the concentration of substrate when the initial velocity,
Vo equals half the maximal velocity:
Km = [S], when Vo = 1/2Vmax

(11)

In the work described in Chapters 3 and 4 of this dissertation, enzyme activity was
measured either by fluorescence (lipid substrates) or absorbance (paranitrophenol
derivative substrates). NPP7 catalytic activity against varying substrate concentrations
was measured in relative fluorescence and absorbance units which were converted to
product concentrations using standard curves based on resorufin and para-nitrophenol,
respectively. The initial velocity (Vo) of the enzyme was determined by taking the slope
(within the linear range) of the activity curve for each substrate concentration. The linear
fit equation from a plot of signal (fluorescence or absorbance) against standard (resorufin
or para-nitrophenol) concentration was used to convert all relative fluorescence and
absorbance units to product concentrations. The resulting initial reaction velocities were
plotted against substrate concentration and rectangular hyperbolic curve fitting [y = m1 *
m2x(1+ m2x)] was done with KaleidaGraph 4.0 (Synergy software, Reading, PA, USA).
In this equation, m1 = Vmax and 1/m2 = Km.
To describe the limiting rate of any enzyme-catalyzed reaction at saturation, a
more general rate constant, k cat is used (23). If the enzyme-catalyzed reaction has several
steps and one is clearly rate-limiting, then kcat is equivalent to the rate constant for that
limiting step (25). When several steps are partially rate-limiting, kcat can become a
complex function of several of the rate constants that define each individual step. In the
Michaelis-Menten equation, kcat = Vmax / [Et] and equation 10 thus becomes
13

Vo = kcat[Et][S] / (k m + [S])

(12)

kcat is also called the turnover number and it is equivalent to the number of substrate
molecules converted to product in a given unit time by a single enzyme active site when
the enzyme is saturated with substrate. The first order rate constant, kcat and has units of
reciprocal time. The kinetic parameters, k cat and Km, are useful in studying and comparing
different enzymes. Each enzyme will have values of k cat and Km that reflect the cellular
environment such as the concentration of substrate normally encountered in vivo by the
enzyme and the chemistry of the reaction being catalyzed. In the results described herein,
the turnover number (kcat) was calculated by dividing the Vmax value by the final enzyme
concentration used in all assays (8.33 nM). This value represents the number of catalytic
cycles or turnovers per enzyme active site per unit time when enzyme is saturated with
substrate (22). The kinetic parameters, k cat and Km also allow the evaluation of the kinetic
efficiency of enzymes although either parameter alone is insufficient for this task. For
instance, two enzymes catalyzing different reactions may have the same k cat value yet the
rates of the uncatalyzed reactions may be different and thus the rate enhancements
brought about by the enzymes may be greatly different (22). The best way to compare
catalytic efficiencies of different enzymes or turnover of different substrates by the same
enzyme is to compare the ratio k cat / Km for the two reactions. This ratio is also called the
specificity constant (23) and is the rate constant for the conversion of E + S to E + P.
When [S] << Km equation 12 reduces to the form
Vo = kcat / Km [Et][S]

(13)
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Vo in this case depends on the concentration of two reactants, [E t] and [S] making kcat /Km
a second order rate constant with units of M-1 s-1. The higher the ratio, the more efficient
the enzyme is for a given substrate (21) however, there is an upper limit to k cat / Km,
imposed by the rate at which E and S can diffuse together in aqueous environment. The
diffusion-controlled limit is 108 to 109 M-1s-1. Enzymes that have a specificity constant
value near this range are said to have achieved catalytic perfection. In this dissertation,
we shall use all these parameters to characterize the catalytic activity of NPP7 and its
mutants against several substrates.

1.5.4

The role of divalent metals in NPP7 catalytic function
The role of divalent metal cations in NPP7 catalytic function is described in

Chapter 5. We have employed both functional (biochemical assays) and structural
(circular dichroism) methods to investigate NPP7 behavior in the presence and absence of
divalent metal cations. Although previous reports indicated that EDTA is necessary for
NPP7 catalytic activity, our findings indicate the opposite is true. In fact, we successfully
used EDTA to significantly reduce the catalytic function of NPP7. Addition of
biologically relevent divalent metals (cobalt, zinc, and nickel) to the inactivated enzyme
restored catalytic activity. In all cases the secondary structure of EDTA and metal ion
treated enzyme did not significantly deviate from untreated controls.
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CHAPTER 2

GENETIC ENGINEERING, SUB-CLONING, PROTEIN EXPRESSION AND
PURIFICATION OF HUMAN NPP7

This project required the ability to express small amounts of wild type and sitedirected mutants of NPP7 for activity determination, as well as the ability to express and
purify larger amounts of native enzyme for biochemical, structural and functional
characterization. To accomplish these diverse goals we utilized two complementary
systems, transient transfection in mammalian cells (HEK293) and baculovirus expression
in insect cells (Sf9). The rationale and methodology used to generate functional enzyme
from these mammalian and insect cell expression systems is detailed in the following
sections.

2.1

Rationale
DNA encoding full length, human NPP7 (Genebank number AY20633) was

generously provided by Dr. Rui-Dong Duan (Lund University, Lund, Sweden). This gene
was supplied in the pcDNA 4/TO/myc–his B mammalian expression vector cloned
between KpnI and NotI restriction sites (Fig. 2.1). The work described herein for NPP7
is part of a larger project to characterize lysophospholipid preferring NPP isoforms.
Thus, the NPP7 expression plasmid provided was modified prior to subcloning to achieve
several goals common to the overall project. First, changes were made to the cloning
sites so that a single insert could be subcloned into both the desired mammalian
19

expression vector (pcDNA3.1(+)) and baculovirus transfer vector (pFASTBac1).
Second, a stop codon was inserted after residue 415 (threonine) to remove the 41 Cterminal residues including the transmembrane anchor to generate a soluble version of the
protein that could be collected from conditioned cell culture medium. Finally, a FLAG
affinity tag (DYKDDDDK) was inserted downstream of the protein sequence (between
T415 and the stop codon) to allow for easy purification. The protein expressed from the
resulting modified insert was a shortened version of the human NPP7 enzyme that was
truncated after the FLAG affinity tag during expression. This modified protein was
referred to as NPP7ExFLAG owing to its extracellular (Ex) localization, as well as the
presence of the FLAG affinity tag. A similarly truncated NPP construct was previously
generated and shown to retain catalytic function (1, 2).
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Fig. 2.1. NPP7ExFLAG genetic engineering scheme. Full length human NPP7 was
provided in the pcDNA4/TO/myc-hisB plasmid (left) cloned between Kpn1 and Not1
restriction sites. Final constructs for NPP7 transient transfection into mammalian cells
(pcDNA3.1+, top right) and baculovirus-mediated infection of insect cells (pFASTBac1,
bottom right). Empty vectors for pcDNA3.1+ (top middle) and pFASTBac1 (bottom
middle) show the relative orientation of Kpn1, BamH1 and Not1 restriction sites.

2.2

Genetic Engineering
All site-directed mutations and PCR insertions were accomplished using the

QuickChange PCR kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s
protocols. The KpnI site (GGTACC) in the parent vector was mutated to a BamH I
recognition sequence (GGATCC) using the sense primer 5’-GCGTTTAAACTTAAG
CTTGGATCCGAAATGAGAG-3’ and antisense primer 5’-CTCTCATGCTTTCG
GATCCAAGCTTAAGTTTAAACGC-3’. In a separate PCR reaction, the FLAG
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affinity-tag (DYKDDDDK) and a stop codon were incorporated at position 416 using the
sense primer 5’-CCCATGCTGCACACAGACTACAAGGACGACGATGACAAGTAG
GAATCTG CTCTTCCG-3’ and antisense primer 5’-CGGAAGAGCAGATTCCT
ACTTGTCATCG TCGTCCTTGTAGTCTGTGTGCAGCATGGG-3’. Plasmids were
isolated from ampicillin resistant colonies using Miniprep kits from Qiagen (Valencia,
CA, USA) according to the manufacturer’s protocols and were verified by complete
nucleotide sequencing of the insert. Fig. 2.2 shows complete amino acid sequences for
the parent, full length NPP7 insert and for the modified truncated FLAG fusion protein.

Human NPP7(wild type)
MRGPAVLLTV ALATLLAPGA
TPNLDAMARD GVKARYMTPA
TTSKVKLPYH ATLGIQRWWD
GVAVTRSRKE GIAHNYKNET
TGHRYGPESP ERREMVRQVD
TVDKRAGDLV EFHKFPNFTF
KDAHPKLHVY KKEAFPEAFH
GEHGFDNKDM DMKTIFRAVG
ANDGHLATLL PMLHTESALP
VILLSEVA
Human NPP7ExFLAG
MRGPAVLLTV ALATLLAPGA
TPNLDAMARD GVKARYMTPA
TTSKVKLPYH ATLGIQRWWD
GVAVTRSRKE GIAHNYKNET
TGHRYGPESP ERREMVRQVD
TVDKRAGDLV EFHKFPNFTF
KDAHPKLHVY KKEAFPEAFH
GEHGFDNKDM DMKTIFRAVG
ANDGHLATLL PMLHTDYKDD

GAPVQSQGSQ
FVTMTSPCHF
NGSVPIWITA
EWRANIDTVM
RTVGYLRESI
RDIEFELLDY
YANNPRVTPL
PSFRAGLEVE
PDGRPTLLPK

NKLLLVSFDG
TLVTGKYIEN
QRQGLRAGSF
AWFTEEDLDL
ARNHLTDRLN
GPNGMLLPKE
LMYSDLGYVI
PFESVHVYEL
GRSALPPSSR

FRWNYDQDVD
HGVVHNMYYN
FYPGGNVTYQ
VTLYFGEPDS
LIITSDHGMT
GRLEKVYDAL
HGRINVQFNN
MCRLLGIVPE
PLLVMGLLGT

GAPVQSQGSQ
FVTMTSPCHF
NGSVPIWITA
EWRANIDTVM
RTVGYLRESI
RDIEFELLDY
YANNPRVTPL
PSFRAGLEVE
DDK

NKLLLVSFDG
TLVTGKYIEN
QRQGLRAGSF
AWFTEEDLDL
ARNHLTDRLN
GPNGMLLPKE
LMYSDLGYVI
PFESVHVYEL

FRWNYDQDVD
HGVVHNMYYN
FYPGGNVTYQ
VTLYFGEPDS
LIITSDHGMT
GRLEKVYDAL
HGRINVQFNN
MCRLLGIVPE

Fig. 2.2. Amino acid sequences for full length NPP7 and truncated
NPP7ExFLAG. The catalytic residue T75 is highlighted in black and the FLAG
affinity sequence is highlighted in grey.
22

2.3

Mammalian cell expression
Mammalian protein expression was used to generate relatively small amounts of

wild type and mutant, human NPP7ExFLAG protein for in vitro functional analysis.

2.3.1

Subcloning of NPP7ExFLAG into pcDNA 3.1(+)
The modified human NPP7ExFLAG insert was subcloned from the parental

pcDNA 4/TO/myc–his B vector into pcDNA3.1(+) (Invitrogen, Carlsbad, CA, USA)
using standard molecular biology techniques. Inserts were liberated using double
digestions with BamH1 and Not1 (New England Biolabs, Ipswich, MA, USA), purified
by Qiagen’s gel extraction protocol (Valencia, CA, USA), and ligated into target vector
that had been digested with BamH1 and Not1 using T4 DNA ligase (New England
Biolabs, Ipswich, MA, USA). Plasmids were isolated from ampicillin-resistant colonies
using Miniprep kits from Qiagen (Valencia, CA, USA) according to the manufacturer’s
protocols and were verified first by agarose gel electrophoresis of NotI and BamHI
double digests and finally by complete nucleotide sequencing of the insert (data not
shown).

2.3.2

NPP7ExFLAG expression in HEK293 cells
Expression of human NPP7ExFLAG protein and site directed mutants was done

by transient transfection in human embryonic kidney (HEK293T) cells using the Polyfect
transfection reagent (Qiagen, Valencia, CA, USA) according to the manufacturer’s
protocols. Briefly, HEK293T cells were seeded in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10% heat inactivated fetal calf serum and 2 mM L-glutamine and
23

100 U/ml penicillin/streptomycin. The cells were grown overnight at 37 oC and 5% CO2
to 80% confluence before transfection with the appropriate NPP7-pcDNA3.1(+) construct
and polyfect reagent. Eight hours after trasfection, the culture medium was changed to
serum-free DMEM, and cells were incubated for an additional 48 hours. Conditioned
medium containing secreted NPP7ExFLAG protein was collected and concentrated using
Centricon 10,000 molecular weight cutoff filters (Millipore, Billerica, MA, USA) by
centrifugation at 3,073 x g for 20 minutes at 4°C. Expression of protein was verified by
Western blot (detailed protocols can be found in section 2.3.3). Concentrated protein was
buffer-exchanged three times into NPP7 assay buffer (10 mM Tris-HCl, 150 mM NaCl,
10 mM taurocholate pH 8.0) using Centricon 10,000 molecular weight cutoff filters
(Millipore, Billerica, MA, USA) by centrifugation at 3,073 x g for 20 minutes at 4°C.
Proteins were stored as 0.5-1.0 µM stocks at 4oC without the addition of adjuvants or
preservatives prior to functional characterization (see discussion in section 2.5).

2.3.3

Verification of NPP7ExFLAG expression
Western blots with the Anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO,

USA) were used to verify protein expression of NPP7ExFLAG and its mutants in
conditioned media of transiently transfected HEK293T cells. Following separation of
proteins using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
on 4-15% gradient gels (Bio-Rad, Hercules, CA, USA), proteins were transferred to
polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA) by
electroblotting at 100V in Tris/Glycine buffer containing 1% SDS and 20% methanol for
1 hour. Nonspecific binding sites were blocked using Tween containing 50 mM Tris
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buffered saline (TBST) (2.7 mM KCl, 138 mM NaCl, 0.5% (v/v) Tween®20 and 5%
(w/v) non-fat dry milk (NFDM). After appropriate washes, the membrane was treated
with Anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO, USA) (1:2000 dilution in
TBST + 3% NFDM). Following additional washes, the membrane was treated with goat
anti-mouse IgG antibody (Sigma-Aldrich, St. Louis, MO, USA) (1:5000 dilution in
TBST + 3 % NFDM). After a final wash, SuperSignal Pico West chemiluminescent
substrate (ThermoScientific, Rockford, IL, USA) was used in conjunction with a digital
imaging system (Fotodyne, Hartland, WI, USA) for detection. Fig. 2.3 shows a sample

NPP7ExFLAG
Mutant 2

NPP7ExFLAG
Wild typeWT

NPP7ExFLAG
Mutant 1

Western blot of NPP7ExFLAG proteins expressed in HEK293 cells.

50kD

Fig. 2.3 Sample Western blot image for NPP7 expression verification.
Three different concentrations (2X, 3X and 5X) of each protein sample were
run and the band intensities obtained reflect the concentration differences.

2.4

Baculovirus expression of NPP7ExFLAG
Baculovirus expression was used to generate large amounts of wild type protein

for structural and functional characterization. Previous research established that NPP7 is
a glycoprotein that lacks activity in the absence of glycoslylation (2, 3). Although insect
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cells lack the ability to perform the complete array of complex glycosylation available in
mammalian cells, they do have the ability to perform simple glycosylation, as well as the
ability to perform other post-translational modifications possible in mammalian systems
(4, 5). Here we chose to use the Bac-to-Bac baculovirus expression system (Invitrogen,
Carlsbad, CA, USA) and Sf9 insect cells.

2.4.1

Subcloning NPP7ExFLAG into pFastBac1
The Kpn1 and Not1 restriction sites present in the parent vector had a reversed

orientation to those in the pFastBac1 transfer vector as shown in Figure 2.1. As was
described in sections 2.1 and 2.2, the Kpn1 site was mutated to a BamH1 recognition
sequence which solved this issue. The NPP7ExFLAG insert was subcloned into
pFASTBac1 in parallel with pcDNA3.1(+) using the same protocols described in section
2.3.1. Bacmid was prepared according to the manufacterer’s protocols. Briefly, after
successful subcloning to generate the pFastBac-NPP7ExFLAG plasmid, the system
required the introduction of a viral expression construct into the pFastBac1 donor vector.
Bacmid DNA is a baculovirus shuttle vector contained in specialized DH10Bac™ E. coli
(Invitrogen, Carlsbad, CA, USA), which also contain a low-copy number mini-F
replicon, kanamycin resistance marker, LacZ gene and a helper plasmid. All of these
components are required to transpose the Tn7 element from the pFastBac donor plasmid
to the mini-attTn7 attachment site on the bacmid to generate a recombinant bacmid (4-7).
The resulting recombinant bacmid DNA was purified using the PureLink HiPure Plasmid
Maxiprep Kit (Invitrogen, Carlsbad, CA, USA) with subsequent verification by PCR
(data not shown).
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2.4.2

NPP7ExFLAG expression in Sf9 insect cells
Sf9 insect cells were seeded in 6-well plates at a density of 9 x 105 cells per well

in 2 ml of Sf-900 III serum free medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 50 µg/mL streptomycin and 50 units/mL penicillin (complete growth medium). The
cells were incubated at 27°C and allowed to attach to the bottom of the wells for 1 hour.
Transfection complexes were prepared using 2 µg bacmid DNA and 9 mL Cellfectin
transfection reagent (Invitrogen, Carlsbad, CA, USA) diluted in 100 mL of
unsupplemented Grace’s medium (Invitrogen, Carlsbad, CA, USA). The complexes were
gently mixed and incubated at room temperature for 30 minutes. Cells were incubated
with the complexes at 27°C for 5 hours after which the DNA/lipid complexes were
removed and replaced with 2 mL of complete growth medium. Following incubation at
27°C for 144 hours, a P1 viral stock resulted. To isolate the P1 viral stock, the
conditioned cell culture medium was collected and centrifuged at 500 x g for five
minutes. The clarified supernatant was then transferred to fresh sterilized tubes, and FBS
was added up to a concentration of 2%. The viral stocks were stored at 4°C protected
from light for up to 2 months.
The P1 viral stock was amplified to a higher titer P2 stock using fresh Sf9 cells.
Sf9 cells were seeded in 6-well plates at a density of 9 x 10 5 cells per well in 2 mL of Sf900 III serum free medium supplemented with 50 µg/mL streptomycin and 50 units/mL
penicillin (complete growth medium). The cells were incubated at 27°C and allowed to
attach to the bottom of the wells for one hour. 50 µL of P1 viral stock were added, and
the cells were incubated at 27°C for 144 hours to generate P2 viral stocks.
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To express large amounts of human NPP7ExFLAG protein, Sf9 cells were
amplified in suspension culture (27°C with orbital shaking at 140 rpm) up to 1 liter in a 3
liter flask. Cells were grown in suspension up to a density of 2 x 106 cells/ mL of
medium before infection with 15 mL of P2 viral stock. Following infection, cells were
incubated at 27°C with shaking at 140 rpm for 72 hours for protein expression. After 72
hours, the conditioned medium was collected and centrifuged at 3,073 x g for 10 minutes
to harvest NPP7ExFLAG. The supernatant was filtered using sterile filtering cups before
protein purification using an Anti-FLAG affinity column (described in section 2.4.3).

2.4.3

Affinity purification of NPP7ExFLAG expressed in sf9 cells
Secreted NPP7ExFLAG protein was purified from conditioned cell culture

medium from baculovirus infected Sf9 cells by affinity chromatography using AntiFLAG M2 agarose beads (Sigma-Aldrich, St. Louis, MO, USA). Clarified conditioned
medium was passed over an Anti-FLAG M2 Gel affinity column (5 mL column volume,
Sigma-Aldrich, St. Louis, MO, USA) equilibrated in TBS buffer (50 mM Tris-HCl, 150
mM NaCl, pH 7.4). Bound protein was washed with 20 column volumes of TBS and then
eluted with TBS containing 50 µg/mL FLAG peptide. The purified protein was
concentrated using Centricon 10,000 molecular weight cutoff filters (Millipore, Billerica,
MA, USA) by centrifugation at 3,073 x g for 20 minutes at 4°C. The concentrated
protein was buffer exchanged into 10 mM Tris-HCl, 10 mM NaCl, pH 7.4 and stored at
4°C without addition of adjuvants or preservatives (see discussion in section 2.5). After
purification, protein expression was verified by SDS-PAGE on 4-15% gradient gels (BioRad, Hercules, CA, USA), as shown in Fig. 2.4. The purified protein is truncated after
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residue 415 (threonine) and the FLAG sequence and has a molecular mass of
approximately 50 kDa, as opposed to the 60kDa molecular mass for the full length
enzyme. It is also noteworthy that the total mass obtained by the sum of all amino acids
including the FLAG-tag is about 48 kDa, but the band obtained on SDS-PAGE is slightly
above 50 kDa, most likely due to post-translational modification(s). Mature human NPP7
is known to be glycosylated at five positions (1) and insect cells are capable of such posttranslational modifications (5, 7).
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Fig. 2.4. SDS-PAGE of affinity purified NPP7ExFLAG. Flow-through fractions
were collected after protein binding onto the column. Elution fractions were collected
using 5ml aliquots of FLAG peptide. Regeneration fractions were collected with 5ml
aliquots of glycine-HCl buffer (pH 3.5).

2.5

Storage of expressed protein
In parallel work on the NPP2 isoform, it was determined that 20% ethylene glycol

was required to stabilize purified enzyme stocks for storage. The use of preservatives
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and/or adjuvants during storage of NPP7 had not been previously reported in the
literature. Thus, we examined the effect of several adjuvants including ethanol, 2-methyl2,4-pentanediol (MPD), and ethylene glycol (EG) (8) on the stability of purified NPP7
stocks. All three adjuvants tested resulted in interference with assays to assess NPP7
function. In contrast, samples of NPP7 stored without additives remained stable and fully
active for more than two months at a minimum concentration of 0.5 μM when stored at
4°C in NPP7 assay buffer (50 mM tris-HCl 150 mM NaCl, pH 8.0) or circular dichroism
(CD) buffer (10 mM tris-HCl, 10 mM NaCl, pH 7.4). Working stocks (25 nM enzyme)
were prepared immediately prior to use for all activity assays.

2.6

References

1

Duan, R., 2003. Identification of human intestinal alkaline sphingomyelinase as a
a novel ecto-enzyme related to the nucleotide phosohodiesterase family,
Biological chemistry, 278: 38528-38536,

2

Wu, J., G. H. Hansen, A. Nilsson and R. D. Duan. 2005. Functional studies of
human intestinal alkaline sphingomyelinase by deglycosylation and mutagenesis,
Biochem J, 386: 153-60,

3

Duan, R. D., 2006. Alkaline sphingomyelinase: an old enzyme with novel
implications, Biochim Biophys Acta, 1761: 281-91,

4

Philipps, B., M. Forstner and L. M. Mayr. 2004. Baculovirus expression system
for magnetic sorting of infected cells and enhanced titer determination,
Biotechniques, 36: 80-3,

30

5

Philipps, B., M. Forstner and L. M. Mayr. 2005. A baculovirus expression vector
system for simultaneous protein expression in insect and mammalian cells,
Biotechnol Prog, 21: 708-11,

6

McCall, E. J., A. Danielsson, I. M. Hardern, C. Dartsch, R. Hicks, J. M. Wahlberg
and W. M. Abbott. 2005. Improvements to the throughput of recombinant protein
expression in the baculovirus/insect cell system, Protein Expr Purif, 42: 29-36,

7

Invitrogen. 2004. Bac-to-Bac Baculovirus Expression System,

8

Ferry, G., N. Moulharat, J. P. Pradere, P. Desos, A. Try, A. Genton, A. Giganti,
M. Beucher-Gaudin, M. Lonchampt, M. Bertrand, J. S. Saulnier-Blache, G. C.
Tucker, A. Cordi and J. A. Boutin. 2008. S32826, a nanomolar inhibitor of
autotaxin: discovery, synthesis and applications as a pharmacological tool, J
Pharmacol Exp Ther, 327: 809-19,

31

CHAPTER 3

THE INFLUENCE OF SUBSTRATE CHAIN LENGTH AND ARCHITECTURE
ON NPP7 CATALYTIC FUNCTION

3.1

Abstract
Nucleotide pyrophosphatase/phosphodiesterase (NPP) 7 is a member of the NPP

family of ectoenzymes. The NPP family consists of seven known isoforms that have been
associated with a wide range of biological effects. NPP7 was discovered 40 years ago but
slow progress has been made toward its structural and functional characterization. It has
previously been shown to hydrolyze three lipid substrates, lysophosphatidylcholine,
platelet activating factor, and sphingomyelin. NPP7 activity against these three substrates
has been associated with human diseases including cancer, atherosclerosis, and
inflammatory bowel disease. In this study, we identify additional NPP7 substrates and
characterize the effect of substrate chain length and architecture on their hydrolysis
through kinetic analysis. Two bioactive lipids (sphingosylphosphorylcholine and lyso
platelet activating factor) and one synthetic small molecule (paranitrophenylphosphocholine) were identified as novel NPP7 substrates. A new
absorbance-based assay method using the identified synthetic substrate is also described.

3.2

Introduction
Nucleotide pyrophosphatase/ phosphodiesterase 7 (NPP7) has previously been

shown to hydrolyze three endogenous lipid substrates, lysophosphatidylcholine (LPC),
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platelet activating factor (PAF), and sphingomyelin (SM) with a lysophospholipase C
activity (1). NPP7 is localized mostly to the GI tract (2) and its activity leads to
generation of signaling messengers implicated in various biological processes associated
with this organ system (1). The hydrolysis of SM is important in the breakdown and
absorption of dietary SM, maturation of the intestinal tract and cholesterol absorption (3).
Hydrolysis of PAF is thought to play a role in suppression of PAF-induced inflammation
in the intestinal tract (4). The hydrolysis of LPC by NPP7 reduces the generation of LPA
by distinct lysophospholipase D enzymes and likely plays a role in decreasing cancer risk
(5). NPP7 is an enzyme with a growing biology that merits understanding in terms of
structure and function. Unfortunately, the substrate profile of NPP7 is limited to these
three known substrates without complete kinetic characterization. Unlike NPP2 (6) and
NPP6 (7), the other known lysolipid preferring phosphodiesterases of the NPP family, a
detailed survey of possible substrates has not been published for NPP7. Such a study
would help elucidate structure–activity relationships to help better understand the
functions of this enzyme.
In the current study, a survey of possible lysolipid substrates of NPP7 has been
conducted. Substrate candidates were selected with varied chain lengths, linkage
functionality, and linker region. All candidates were subjected to full kinetic analysis of
their hydrolysis by human NPP7.
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3.3

Materials and Methods

3.3.1

NPP7 plasmid design
The gene coding for full length, human NPP7 contained within the pcDNA

4/TO/myc–his B mammalian expression vector was generously donated by Dr. Rui-Dong
Duan of Lund University (Lund, Sweden). The insert originally contained Kpn1
(upstream) and Not1 (downstream) cloning sites. To make this insert compatible with the
pFASTBac1 vector, the KpnI site (GGTACC) in the parent vector was mutated to a
BamH I recognition sequence (GGATCC) using the sense primer 5’-GCGTTTAAAC
TTAAGCTTGGATCCGAAATGAGAG-3’ and antisense primer 5’-CTCTCATGCTT
TCGGATCCAAGCTTAAGTTTAAACGC-3’. In a separate PCR reaction the FLAG
affinity-tag (DYKDDDDK) and a stop codon were incorporated at amino acid position
416 using the sense primer 5’-CCCATGCTGCACACAGACTACAAGGACGACG
ATGACAAGTAGGAATCTGCTCTTCCG-3’ and antisense primer 5’CGGAAGAGCAGATTCCTACTTGTCATCGTCGTCCTTGTAGTCTGTGTGCA
GCATGGG-3’. The Quickchange PCR kit (Stratagene, La Jolla, CA, USA) was used for
all mutagenesis according to the manufacturer’s protocols. All mutants were verified
through complete nucleotide sequencing before further manipulation. Truncation of
NPP7 at amino acid position 416 (to generate the construct NPP7ExFLAG) has
previously been shown to generate functional, extracellularly localized protein (8). To
allow for high capacity protein production and purification, the NPP7ExFLAG insert was
used to generate a recombinant bacmid using the Bac-to-Bac system (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocols. Bacmid DNA was
purified using the PureLink HiPure Plasmid Maxiprep Kit (Invitrogen K2100-06,
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Carlsbad, CA, USA) and verified by PCR. Recombinant Bacmid DNA was transfected
into Sf9 cells in the presence of Cellfectin transfection reagent (Invitrogen, Carlsbad, CA,
USA) to generate viral stocks. High titer viral stocks were obtained after a second 7 day
infection.

3.3.2

NPP7 protein expression and purification
For protein expression, Sf9 cells were amplified to a density of 2 x 106 cells/mL in

a 1L cell culture suspension before the addition of high titer viral stock (15 mL). After 72
hours of infection, conditioned medium was collected and clarified by centrifugation at
3,073 x g for 10 minutes. The supernatant was filtered using 0.22 μm sterile filtering
cups (Millipore, Billerica, MA, USA) before protein purification.
The filtered media was purified using an Anti-FLAG M2 Gel affinity column
(Sigma-Aldrich, St. Louis, Mo, USA) equilibrated in TBS buffer (50 mM Tris, 150 mM
NaCl, pH 7.4). Bound proteins were washed with 20 column volumes of TBS and then
eluted with TBS containing 500 μg/mL FLAG peptide (Sigma-Aldrich, St. Louis, MO,
USA). Purified proteins were concentrated and buffer exchanged into 10 mM Tris, 10
mM NaCl, pH 7.4 using Centricon 10,000 MWCO filters (Millipore, Billerica, MA,
USA). Protein purity was verified by SDS-PAGE with Coomassie staining and Western
blot.

3.3.3

NPP7 catalytic activity assays
Fluorescence-based assay: Hydrolysis of all lipid substrates was monitored using

a modification of Invitrogen’s Amplex Red phospholipase C assay to detect released
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phosphatidylcholine. NPP7ExFLAG catalytic activity was monitored via fluorescence
determination (excitation 571 nm and emission 585 nm) every minute for 1 hour using a
Synergy2 multiwell plate reader (BioTek Instruments Inc., Vermont, USA). Each well
on the plate was loaded with a total of 60 μL consisting of substrate, Amplex Red
cocktail (10 μM Amplex Red reagent, 0.1 U/mL choline oxidase, 1 U/mL horseradish
peroxidase, 4 U/mL alkaline phosphatase) and recombinant, purified NPP7ExFLAG
(8.33 nM). All components were prepared in NPP7 assay buffer containing 50 mM TrisHCl, pH 8.0, 150 mM NaCl, and 10 mM sodium taurocholate (2) without the previously
described 2 mM EDTA.
Absorbance-based assay: Hydrolysis of all synthetic, para-nitrophenol
containing substrates was done using an absorbance assay based on the paranitrophenolate product that has a maximum absorbance at 405 nm. Each well on the plate
was loaded with a total of 60 µL consisting of substrate and enzyme in NPP7 assay
buffer. NPP7ExFLAG activity was monitored by the level of absorbance at 405 nm for a
1 hour period using a Synergy2 multiwell plate reader (BioTek Instruments Inc.,
Vermont, USA).

3.3.4

Calculation of kinetic parameters
NPP7 catalytic activity against varying substrate concentrations was measured in

relative fluorescence and absorbance units which were converted to product
concentrations using standard curves based on resorufin and para-nitrophenol,
respectively. The initial velocity of the enzyme-catalyzed reaction was determined by
taking the slope (within the linear range) of the activity curve for each substrate
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concentration. The linear fit equation from a plot of signal (fluorescence or absorbance)
against standard (resorufin or para-nitrophenol) concentration was used to convert all
relative fluorescence and absorbance units to product concentrations. The resulting initial
reaction velocities were plotted against substrate concentration and rectangular
hyperbolic curve fitting [y = m1 * m2x(1+ m2x)] was done with KaleidaGraph 4.0
(Synergy software, Reading, PA, USA). In this equation, m1 = Vmax and 1/m2 = Km. The
turnover number (kcat) was calculated by dividing the Vmax value by the final enzyme
concentration used in all assays (8.33 nM). This value represents the number of catalytic
cycles or turnovers per enzyme active site per unit time when enzyme is saturated with
substrate (9). We further calculate the enzyme’s catalytic efficiency for each substrate
hydrolyzed using kcat/Km ratio. The higher the ratio, the more efficient the enzyme is for a
given substrate (10).

3.4

Results

3.4.1

Expression and purification of human NPP7ExFLAG
The expression and localization of human NPP7 in Sf9 insect cells was analyzed

at 48, 72, and 96 hours after infection with high titer baculoviorus stocks by Western blot
as shown in Fig. 3.1A. The majority of the expressed protein was localized within the
cell pellet but a significant minority was localized to the less complex concentrated
conditioned medium (CCM) For the experiments outlined herein, only that material
localized to the CCM was purified by anti-FLAG affinity chromatography and used for
enzyme assays (Fig. 3.1B). The truncated NPP7ExFLAG protein band has a predicted

37

molecular weight of 48 kDa but the protein bands appear slightly above 50 kDa probably
due to post-translational modifications.
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Fig. 3.1. Western blot of NPP7ExFLAG expressed in sf9 cells. (A). Trial expressions
were performed to obtain the optimal expression time in Sf9 insect cells. The amount of
truncated NPP7ExFLAG secreted in the medium was analyzed after 48, 72, and 96 hours.
(B). Coomassie stained SDS-PAGE of purified NPP7ExFLAG.

3.4.2

Effect of EDTA on NPP7 activity
Previously, Duan et al. suggested that zinc inhibited NPP7 activity and that EDTA

reversed this effect (2). These results are difficult to rationalize based on the knowledge
that NPP7, like all NPP isoforms, is a metalloenzyme (11) that is presumed to require
divalent metals in its active site for catalytic activity. We have recently shown that
EDTA is an effective inhibitor of all known lysolipid preferring NPP isoforms (Pham et
al., manuscript in preparation). Here we show that treatment with EDTA at 2 mM
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significantly blocks NPP7ExFLAG activity using the substrates LPC (16:0), PAF (16:0),
and SM (Fig. 3.2). This figure shows single concentration data at a single assay time
point in which hydrolysis of substrate versus time was linear in the absence of EDTA.

120

%Response

100

80
60
40
20
0
50uM LPC16:0

75uM PAF16:0

25uM SM

Substrates used

Fig. 3.2. Effect of EDTA on NPP7ExFLAG catalytic activity. Hydrolysis of
PAF16:0, LPC16:0 and SM by 8.33nM NPP7 was analyzed using the Amplex Red
assay, in the presence (black bars) and absence (white bars) of 2 mM EDTA in the
assay buffer. All activities are normalized to that of SM without EDTA.

3.4.3

Hydrolysis of SM and SPC
Fig. 3.3 shows Michaelis-Menten plots of initial velocity versus substrate

concentration for NPP7ExFLAG mediated hydrolysis of both SM and SPC using the
Amplex Red fluorescence method as described in materials and methods. A panel of
kinetic parameters determined experimentally for the hydrolysis of SM and SPC are
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shown in Table 3.1. The Km values of 23 ± 1.3 μM for SM and 56 ± 1.4 μM for SPC
indicate a 2.4-fold greater affinity for SM by NPP7ExFLAG. The maximal velocity
(Vmax) and the relative turnover number (k cat) for hydrolysis of SPC were approximately
10% higher than SM. Based on these data the calculated specificity constant (kcat/Km) for
SM was twice that of SPC meaning that NPP7 exhibits a higher catalytic efficiency
against SM than SPC at physiological conditions (12).
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Fig. 3.3. Hydrolysis of SM and SPC by NPP7ExFLAG. (A). Varying concentrations of SM and
SPC were used to obtain initial velocities using the Amplex Red assay. Plots of substrate
concentration versus initial velocity were generated using the KaleidaGraph software package. The
equation of each nonlinear curve, y= m1m2x/(1+m2x), was used to obtain values for Km and Vmax
for each substrate (Table 3.1). Final values were obtained from the average of three triplicate runs.
Both SM and SPC have the basic structure shown in panel B.
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Table 3.1. Kinetic parameters for the hydrolysis of SM and SPC.
Substrate

Km (µM)

Vmax (μM/sec)
(x10-2)

kcat (sec-1)

kcat/Km (M-1sec-1)
(x104)

SM
SPC

23 ± 1.3
56 ± 1.4

3.3 ± 0.1
3.6 ± 0.02

3.9 ± 0.11
4.3 ± 0.02

17.0 ± 5.8
8.0 ± 2.6

3.4.4

Hydrolysis of LPC
Plots of initial velocity versus substrate concentration for NPP7ExFLAG

mediated hydrolysis of LPC species are shown in Fig. 3.4A. Summaries of kinetic
parameters obtained for each LPC species are compiled in Table 3.2. GPC, the smallest
LPC species (where the sn-1 fatty acid has been replaced with a hydrogen), had the
smallest Km value of 25 μM but its turnover number (k cat) was at least eight times less
than the other LPC species examined. LPC14:0, LPC16:0 and LPC18:0 had similar
affinities (Km = 38 μM, 41 μM and 33 μM, respectively) and a one way ANOVA
statistical analysis followed by the Bonferroni’s post test showed no significant
difference in the Km values for these three substrates. LPC14:0 had a slightly larger k cat
value of 2.1 sec-1 compared to that of LPC16:0 and LPC18:0 (1.6 sec-1 for both). The
kcat/Km values (5.5 x 104, 4.0 x 104, and 4.8 x 104 M-1 sec-1 for LPC14:0, LPC16:0, and
LPC18:0, respectively) show that NPP7 hydrolyzed LPC14:0 more effectively. The
specificity constants for LPC14:0 and LPC16:0 were statistically different with a p value
of <0.0001. For the shorter chain lengths of LPC tested (LPC10:0 and LPC12:0), the rate
of hydrolysis decreased with decreasing chain length as shown by the kinetic parameters.
LPC10:0 had the highest Km value of 371 μM and a specificity constant six times smaller
than the longer chained LPC species.
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Fig. 3.4. Hydrolysis of LPC by NPP7ExFLAG. Glycerophospholipids of varying chain length and
linker functionality were used to obtain initial velocities with 8.33 nM of NPP7ExFLAG. Panel A is
comparison of the hydrolysis of LPC species. Panel B is a comparison of PAF versus LPAF
hydrolysis
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Table 3.2. Kinetic parameters for hydrolysis of glycerophospholipids
Vmax (μM/sec)
Substrate

3.4.5

Km (µM)

-1

kcat (sec )

(x10-2)

kcat/Km (M-1sec-1)
(x104)

GPC

25 ± 1.0

0.1 ± 0.084

0.1 ± 0.01

0.4 ± 0.11

LPC10:0

371 ± 6.0

0.7 ± 0.002

0.9 ± 0.02

0.2 ± 0.12

LPC12:0

68 ± 1.0

0.6 ± 0.003

0.8 ± 0.03

1.2 ± 0.14

LPC14:0

38 ± 0.7

2.0 ± 0.029

2.1 ± 0.02

5.5 ± 2.1

LPC16:0

41 ± 0.3

1.3 ± 0.012

1.6 ± 0.01

4.0 ± 0.6

LPC18:0

33 ± 0.7

1.3 ± 0.033

1.6 ± 0.04

4.8 ± 1.8

PAF16:0

73 ± 1.0

1.8 ± 0.030

2.2 ± 0.03

3.0 ± 1.2

LPAF16:0

21 ± 0.3

2.2 ± 0.180

2.7 ± 0.22

12 ± 5.8

LPAF18:0

14 ± 0.03

2.3 ± 0.050

2.8 ± 0.07

20 ± 4.8

Hydrolysis of PAF and lysoPAF
PAF16:0 has previously been shown to be a substrate for NPP7 (4). Here a

complete kinetic analysis of NPP7ExFLAG mediated hydrolysis of PAF 16:0 and two
lysoPAF species (16:0 and 18:0) were completed. Representative Michaelis-Menten
plots of initial velocity versus substrate concentrations for the hydrolysis of these
substrates are shown in Figure 3.4B. The kinetic parameters determined from this
analysis are compiled in Table 3.2. LysoPAF species had affinities that were
approximately 3.5 to 5 times better (K m values lower) than PAF 16:0. Likewise, the
lysoPAF species had apparent affinities better by a factor of about two when compared to
their corresponding LPC analogs. Maximal reaction velocities were the highest for
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lysoPAF 16:0 and 18:0, as compared to both PAF and corresponding LPC analogues.
NPP7 also exhibited a significantly higher catalytic efficiency for lysoPAF as shown by
higher kcat/Km valuesin Table 3.2.

3.4.6

Hydrolysis of synthetic compounds
Several synthetic substrates previously tested as substrates for either NPP2 (6, 13,

14) or NPP6 (7) were selected and examined as substrates for NPP7ExFLAG. No
NPP7ExFLAG catalytic activity was detected with FS-3 and para-nitrophenyl phenyl
phosphate (pNPPP) (data not shown). Likewise, only minimal activity was observed
when bis-para-nitrophenylphosphate (bis-pNPP) or para-nitrophenylthymidine
monophosphate (pNP-TMP) were used as substrates as evidenced by the very low paranitrophenolate signal determined at 405 nm (Fig. 3.5 A).
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Fig. 3.5. Hydrolysis of synthetic nitrophenyl substrates by NPP7EXFLAG.
Accumulation of the p-nitrophenolate anion from hydrolysis of 1mM pNPPC and 50mM
bis-pNPP and pNP-TMP after 1 hour (A). The saturation curve for NPP7 hydrolysis of
pNPPC (B).

Table 3.3 Kinetic parameters for the hydrolysis of synthetic substrates.
Substrate

Km
(µM)

Vmax (μM/sec)
(x10-2)

kcat (sec-1)

kcat/Km (M-1 sec-1)
(x104)

pNPPC

83 ± 5

2.0 ± 0.02

2.4 ±
0.022

2.9 ± 0.8

pNPTMP
Bis-pNPP

N/A: Minimal activity
N/A: Minimal activity
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It is evident from Fig. 3.5A that para-nitrophenyl phosphocholine (pNPPC) is a
much better substrate for NPP7ExFLAG than the other para-nitrophenyl containing
compounds tested. Here single concentrations of each substrate (1 mM pNPPC and 50
mM of either bis-pNPP or pNP-TMP) are compared at a single assay time where the
pNPPC hydrolysis rate was linear. Due to low activity, no kinetic parameters could be
determined for bis-pNPP or pNP-TMP. In contrast, a Michaelis-Menten saturation curve
for the hydrolysis of pNPPC is shown in Fig. 3.5(B) and Table 3.3 shows the calculated
kinetic parameters. pNPPC had an apparent K m value of 83 μM and Vmax of 0.2 µM∙sec1

. The Vmax, kcat and specificity constant values obtained for pNPPC were comparable to

those obtained for the hydrolysis of PAF16:0 (Table 3.2).
The catalytic effiency for the hydrolysis of each tested substrate by NPP7 was
compared by a plot of k cat/ Km shown in Figure 3.6. The graph shows the k cat/ Km values
obtained for the hydrolysis of each substrate by NPP7 arranged based on the substrate
groups tested. The enzyme exhibited greater catalytic efficiency against SM than SPC.
Both lysoPAF species were hydrolyzed more efficiently than PAF16:0, the previously
known substrate, but lysoPAF18:0 was the most efficiently utilized substrate by this
enzyme. Statistical significance of the k cat/ Km values for lysoPAF18:0 and SM were
calculated by the one way ANOVA software followed by the Bonferroni’s post test
(KnowWare International, Inc, Denver, CO, USA) and gave a p value of <0.0001.
Catalytic efficiency against various LPC chain lengths is also shown and the statistical
analysis confirmed higher efficiency for the hydrolysis of LPC14:0 than LPC16:0. There
was no statistical difference in catalytic efficiency against LPC16:0 and LPC18:0.
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Fig. 3.6. Comparison of NPP7 catalytic efficiency against all substrates. The
catalytic efficiency of NPP7 against previously known and newly identified
substrates as depicted by the k cat/Km values is plotted on the y-axis. The statistical
difference between the k cat/Km values for LPC14:0 and LPC16:0 was calculated
using the one way ANOVA analysis followed by the Bonferroni post test analysis.
The p value obtained was <0.0001 as represented by the three asterisks (***) in the
graph.

3.5

Discussion
NPP isoforms have been reported to possess overlapping substrate specificity (6,

15). NPP2 is known to hydrolyze LPC and SPC but not PAF or SM (16). Similarly,
NPP6 has been shown to hydrolyze LPC, SPC, and lysoPAF but not PAF or SM (7).
Here, we have shown that NPP7 is a more promiscuous lipid preferring isoform within
the NPP family that is capable of hydrolyzing glycerolipids (LPC, PAF, lysoPAF) and
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sphingolipids (SPC and SM), as well as para-nitrophenol containing substrates. This
makes NPP7 the only NPP isoform that has the ability to utilize substrates with more than
one long hydrocarbon chain in their structures. The results show that NPP7 has a
preference for large lipid substrates. NPP7ExFLAG showed very little activity toward
GPC, the smallest natural substrate tested. Likewise, NPP7ExFLAG failed to utilize bispNPP, pNPPP, and pNP-TMP as substrates even in the mM concentration range. In
contrast, NPP7ExFLAG did utilize pNPPC as a substrate despite its small size. The
hydrolysis of pNPPC was similar to that of PAF 16:0 based on the panel of kinetic
parameters determined. The calculated specificity constants (k cat/Km values) indicate that
lysoPAF 18:0 was the best NPP7ExFLAG substrate, while lysoPAF 16:0 and SM
followed closely.
Further research is needed to identify the biological implications, if any, that these
newly identified NPP7 substrates present. SPC is a bioactive lipid known to activate a
number of signaling cascades via G protein-coupled receptors although it is present in
relatively low concentrations in human serum (17, 18). Synthetic and degradative
pathways for SPC are not well understood but Xin et al. recently presented several
theories (from SM, sphingosine and S1P) by which SPC accumulation could be possible
(17). SPC is an effective mitogen for various cell types and its levels are upregulated in
several pathological conditions including Niemann-Pick disease and ovarian cancer (17,
18). The hydrolysis of SPC by NPP7 generates sphingosine, an antiproliferative
messenger. In contrast, the hydrolysis of SPC by NPP2 generates sphingosine-1phosphate, a regulator of migration (16). This finding again presents NPP7 as the
anticancer NPP isoform as opposed to NPP2 which is a mediator of cancer development
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and progression (19). Our finding has thus identified a possible SPC catabolic pathway
for which the biological importance remains to be understood.
LysoPAF is the main metabolite and precursor for the biosynthesis of PAF via the
remodeling pathway under normal, as well as inflammatory conditions (20). Recently
lysoPAF was reported as a bioactive lipid with effects opposing those of PAF (21).
NPP7ExFLAG hydrolyzed lysoPAF five times more effectively than PAF. The
physiological levels and bioactivity of PAF are tightly controlled by inter conversion to
lysoPAF by PAF acetylhydrolases (20). Our findings suggest that NPP7 might play a
role in the regulation of PAF by contributing to the clearance of its main metabolite and
precursor but further studies are needed to analyze the effects of NPP7 on PAF/lysoPAF
metabolism and bioactivity.
Conversion of LPC16:0 to monoacylglycerol and phosphorylcholine by NPP7 has
been known for some time but the influence of chain length on hydrolysis has not been
explored in this type of kinetic analysis (22). LPC16:0 has been predominantly used in
previous work to characterize NPP7 (3, 5, 23, 24). For the first time, this work has
established that LPC14:0 is the preferred chain length for NPP7ExFLAG. For LPC chain
lengths shorter than 12, affinity was decreased based on the K m values obtained.
NPP7ExFLAG had the highest apparent affinity for GPC, the LPC substrate completely
lacking an acyl chain. However, GPC displayed the poorest conversion to products as
indicated by the lowest k cat value of 5 x 103 M-1 sec-1. NPP6 is the only other
lysophospholipase C in the NPP family and was previously reported to hydrolyze
LPC12:0 and GPC with the highest preference (7).
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Para-nitrophenylphosphocholine (pNPPC) is a synthetic NPP7 substrate identified
here for the first time. Kinetic parameters for the NPP7ExFLAG mediated hydrolysis of
pNPPC were similar to those obtained for PAF16:0. NPP7 cleaves pNPPC with a
lysophospholipase C activity, generating phosphocholine which can be monitored by
fluorescence (Amplex Red assay) and para-nitrophenolate anion which can be monitored
by absorbance at 405 nm. We have thus described a new assay method for monitoring
NPP7 catalytic activity using this novel substrate. The use of radio-labeled lipid
substrates has been the predominant method for monitoring NPP7 activity (4, 5, 8, 25)
but this method is labor intensive, time consuming and expensive. These new, alternative
methods are an improvement over the previous method in both cost and ease of use. The
Amplex Red fluorogenic assay indirectly measures phosphocholine production via a
series of exogenous enzymatic reactions to generate resorufin. The absorbance assay
based on pNPPC is inexpensive and is based on a direct NPP7 product (paranitrophenolate anion). Both approaches provide for multiplex, multiwell plate analysis
that allows for the type of complete kinetic analysis provided here for NPP7.
Successful baculovirus expression of a truncated, biologically active
NPP7ExFLAG construct has been described herein. NPP7 has been suggested to have
five glycosylation sites and that mature enzyme is inactive without appropriate Nglycosylation (5). Insect cells are capable of expressing protein with post-translational
modifications similar to mammalian cells (26). The molecular weight of the
NPP7ExFLAG construct is approximately 48 kDa. The expressed protein migrated to a
position slightly above 50 kDa on SDS-PAGE and Western blots, indicating posttranslational modification occurs in Sf9 insect cells.
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NPP7 has been reported to be inhibited by zinc and the inhibitory effects were
prevented by 2 mM EDTA (2). Since this report, 2 mM EDTA has been a component of
the NPP7/Alk-SMase assay buffer in all published NPP7 experiments (4, 24, 27).
Contrary to previous reports, we establish here that NPP7/Alk-SMase catalytic activity is
greatly hampered by EDTA. The current finding is not unusual considering NPP7 is a
metalloenzyme which depends on the presence of divalent cations for its catalytic
function (24). The chelating abilities of EDTA may disrupt the metal enzyme
interactions leading to reduced catalytic activity. Further investigations are underway to
find out if this effect is dependent on EDTA concentration and/or time of exposure.
In conclusion, two cheaper, easier and multiplex methods for the assay of NPP7
catalytic activity have been established as alternatives to the common use of radio-labeled
substrates. Through these methods, we have extensively characterized and compared the
kinetics of this enzyme against all its substrates. Several new substrates have been
identified that may have biological implications but further research is needed to identify
and characterize such effects.
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CHAPTER 4

COMPUTATIONAL IDENTIFICATION AND BIOCHEMICAL
CHARACTERIZATION OF SUBSTRATE BINDING DETERMINANTS OF
NUCLEOTIDE PYROPHOSPHATASE/ PHOSPHDIESTERASE-7

4.1

Abstract
The nucleotide pyrophosphatase/phosphodiesterase (NPP) subfamily of alkaline

phosphatases currently consists of seven human isoforms that are related in structure and
function. They are all ectoenzymes that hydrolyze a wide variety of substrates to generate
lipid messengers that mediate a range of physiological and pathological processes. NPP
isoforms have been associated with conditions such as cancer, obesity, bone
mineralization, allergy, growth, and development. Thus, they are attractive targets in drug
discovery and development, however, they are not well understood in terms of their
structure and function. NPP7 is a recent addition to this important family of enzymes. It
hydrolyzes lipid substrates that lead to generation of both proliferative and
antiproliferative messengers such as ceramide, sphingosine, and sphingosine 1phosphate. Like other NPPs, NPP7 recognizes a spectrum of substrates preferentially but
it is not well understood what determines its well-defined substrate preferences. The aim
of this work is to identify and characterize amino acid residues that contribute to substrate
recognition by NPP7.
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4.2

Introduction
Nucleotide pyrophosphatase/phosphodiesterase-7 (NPP7) is a 60kDa membrane

anchored ectoenzyme that hydrolyzes sphingomyelin (SM) (Nilsson 1969), platelet
activating factor (PAF) (Wu et al. 2006), lysophosphatidylcholine (LPC) (Wu et al.
2005), sphingosylphosphorylcholine (SPC) and lyso platelet activating factor (lyso PAF)
(Wanjala I.W., A.L. Parrill and D.L. Baker, manuscript in preparation) to generate
multiple signaling molecules. The enzyme has been implicated in pathological conditions
such as cancer and atherosclerosis, as well as in normal physiological processes such as
cholesterol absorption and maturation of the intestinal tract (Wu et al. 2006). However,
NPP7 has not been well characterized in terms of its structure and function (Duan 2006).
The nucleotide pyrophosphatase/phosphodiesterase (NPP) enzymes comprise a seven
member subfamily of enzymes (Bollen et al. 2000). Individual NPP isoforms are
classified as either pyrophosphatases or phosphodiesterases depending on the specific
substrates they hydrolyze (Kanda et al. 2008). NPP1, NPP2, and NPP3 are nucleotide
pyrophosphatases that cleave inorganic phosphate from nucleotides and their derivatives
(Clair et al. 1997; Gijsbers et al. 2003). In contrast, NPP2, NPP6, and NPP7 are
phosphodiesterases that hydrolyze phosphodiester bonds in lipids and their derivatives,
(Duan 2003; Sakagami et al. 2005; Umezu-Goto et al. 2002). NPP4 and NPP5 are yet to
be characterized in terms of substrate preferences. NPP2 is the only member of the seven
known NPP isoforms that possesses both pyrophosphatase and phosphodiesterase
activities (Stefan et al. 2005). As a phosphodiesterase, NPP2 exhibits lysophospholipase
D (LPLD) (Umezu-Goto et al. 2002) activity which contrasts with the lysophospholipase
C (LPLC) activities of NPP6 and NPP7. Besides these specific activities, no previous
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experimental evidence is available to explain differences in substrate preference among
the known lipid preferring NPP isoforms. (Bollen et al. 2000; Gijsbers et al. 2001)
NPP7 has been previously shown to hydrolyze SM, LPC, and recently, we have
also identified lyso platelet activating factor (lysoPAF), sphingosyl-phosphorylcholine
(SPC), and para-nitrophenylphosphorylcholine (pNPPC) as additional NPP7 substrates
(Wanjala, I.W., A.L.Parrill and D.L. Baker, manuscript in preparation). Here we have
used a combination of computational homology modeling, substrate docking, sitedirected mutagenesis and kinetic analysis of enzyme activity to examine the role of
specific amino acid residues within the NPP7 active site in determining substrate
recognition. Homology modeling has not previously been applied to the analysis of
NPP7 structure and function relationships and this work could open a new approach in
the analysis of this important isoform. Our results suggest an overlapping binding pocket
for all substrates examined and show that NPP7 activity against four of its substrates was
differentially affected by specific site-directed mutations.

4.3

Materials and Methods

4.3.1

Generation of the NPP7 homology model
The bacterial Xac NPP structure (2gso) (Zalatan et al. 2006) was used as the

template sequence and the human NPP7 nucleotide sequence (Genbank code AY20633)
(Duan 2003) as the target for homology modeling. Xac NPP is the most closely related
analog of human NPP isoforms with a solved crystal structure, similar function, and
relatively high sequence homology. The Molecular Operating Environment (MOE 2008)
software package (Chemical Computing Group, Montreal, Canada) was used for all
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homology modeling and docking. A database of eleven homology models was generated
and each model was analyzed using a Ramachandran plot to identify those models with
phi/psi angles outside the range represented in known crystal structures (outliers). Models
were ranked based on the number of outliers and their proximity to the catalytic residue
(threonine 75). The best models were those with fewer outliers that were located more
than 10Å from the active residue. The selected model was then energy minimized using
the Assisted Model Building and Energy Refinement (AMBER99) force field (Asada et
al. 2002; Hornak et al. 2006; Wang et al. 2000) to generate the final model with which
subsequent substrate docking was performed.

4.3.2

Substrate docking
Substrate docking was used to study interactions between NPP7 and its

previously known substrates and their closely related analogs. pNPPC was directly
docked into the active site as a whole molecule since it is small and has limited
flexibility. The substrates LPC, PAF, and SM are highly flexible because of long fatty
acyl chains in their structures. For this reason stepwise docking was done starting with
the polar head groups of each substrate. Wall restraints were also used to keep the
substrate phosphate group in close proximity to the enzyme’s active residue, threonine
75. The hydrophobic chains were then extended three carbon atoms at a time followed by
energy minimization for the newly added atoms at each step. The protein surface feature
within MOE was used to visualize the various channels that could accommodate the
substrates during binding. After extending the full chains, chain rotations were done
followed by energy minimization to explore the best positions for each chain and thus the
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minimum energy conformation for each substrate. The lowest energy conformation was
then selected for each substrate and their interactions with the protein analyzed.

4.3.3

Analysis of protein-substrate interactions
Protein residues within 4.5 Å of the substrate atoms were analyzed to determine

the presence of non-covalent interactions. Presence of such interactions was taken as
evidence of higher affinity binding than complexes lacking such stabilizing interactions.
All protein residues around the common substrate groups were identified and the
distances separating them from the possible interaction points analyzed. The maximum
interaction distance was set at 4.5 Å. All residues more than 4.5 Å away from their
possible interaction points in all substrates were eliminated as noncovalent interaction
strengths become weaker with increasing distance. The type of interaction formed by
each residue was also analyzed. Stronger noncovalent interactions such as H-bonding, πstacking and cation-π interactions were considered more important than weaker
interactions such as Van der Waal’s forces. Six mutation candidates were selected and the
type of effect expected with a given type of single point mutation predicted.

4.3.4

Site-directed mutagenesis of NPP7
The full length, human NPP7 insert (Genbank AY20633) contained within the

mammalian expression vector pcDNA4/TO/myc his B, was kindly provided by Dr. Rui
Dong-Duan (Lund University, Lund, Sweden). The upstream cloning site was mutated
from the Kpn1 to a BamH1 recognition sequence using the sense primer 5’GCGTTTAAACTTAAGCTTGGATCCGAAATGAGAG-3’ and antisense primer 5’60

CTCTCATGCTTTCGGATCCAAGCTTAAGTTTAAACGC-3’ and the Quickchange
site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the
manufacturer’s protocols. The NPP7 insert was subcloned into the pcDNA3.1(+)
mammalian expression vector using standard molecular biology approaches. Next, a
truncated, secreted version of NPP7 containing a FLAG affinity tag was generated by
adding the sequence DYKDDDDK after T415 and before a stop codon using the sense
primer 5’-CCCATGCTGCACACAGACTACAAGGACGACGATGACAAGTAG
GAATCTGCTCTTCCG-3’ and antisense primer 5’-CGGAAGAGCAGATTCCTA
CTTGTCATCGTCGTCCTTGTAGTCTGTGTGCAGCATGGG-3’ with the
Quickchange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to
the manufacturer’s protocols. This truncated NPP7 construct lacked the C-terminal
transmembrane anchor but has previously been shown to be functional and expressed as a
secreted enzyme (Wu et al. 2005). The complete affinity tagged fusion was termed
NPP7ExFLAG. All proposed site directed mutants were generated from this customized
plasmid using standard PCR techniques and the multi site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s protocols. Table 4.1
lists all the sense primers used to prepare all site directed mutants.
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Table 4.1 Sense primers for NPP7ExFLAG mutants
Mutation
Sense primer
F80A

5’-TGACCAGCCCCTGCCACGCCACCCTGGTCACCGGC-3’

L107F

5’-ACCACCAGCAAGGTGAAGTTCCCCTACCACGCCAC-3’

Y142A

5’-TGGCTCCTTCTTCGCCCCGGGCGGGAACGT-3’

Y166A

5’-GGCATCGCACACAACGCCAAAAATGAGACG-3’

E169A

5’-TCGCACACAACTACAAAAATGCGACGGAGTGGAGAG-3’

E169Q
F275A

5’-TCGCACACAACTACAAAAATGAGACGGAGTGGAGAG-3’
5’-CGGGACATCGAGTTTGAGCTCCTGGACTAC-3’

4.3.5

Mutant protein expression and normalization
Wild type NPP7ExFLAG and all mutant proteins were expressed via transient

transfection in human embryonic kidney cells (HEK293T). HEK293T cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat-inactivated fetal
calf serum and 2 mM L-glutamine and 100 U/ml penicillin-streptomycin at 37 oC and 5%
CO2 up to 80% confluence. Transient transfections with wild type or mutant
NPP7ExFLAG insert subcloned in the pcDNA3.1(+) mammalian expression vector were
done using the Polyfect transfection reagent (Qiagen, Valencia, CA, USA) according to
the manufacturer’s protocols. Eight hours after transfection, the culture medium was
changed to serum-free DMEM and cells were incubated for an additional 48 additional
hours. Conditioned media containing secreted NPP7 protein was collected and
concentrated using 10,000 molecular weight cutoff (10K MWCO) filters (Millipore,
Billerica, MA, USA) by centrifugation at 3073xg for 20 minutes. NPP7 proteins (wild
type and mutants) present in concentrated conditioned medium (CCM) were stored at 4o C
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in NPP7 assay buffer, pH 8 without addition of adjuvants until functional activity was
determined.
Western blots were used to verify expression of NPP7ExFLAG and all its
mutants. The M2 Anti-FLAG antibody (Sigma-Aldrich, St. Louis, MO, USA) was
utilized following standard protocols. Following separation by SDS-PAGE on Tris-HClgradient gels (4-15%, Bio-Rad, Hercules, CA, USA) proteins were transferred onto
polyvinylidene difluoride (PVDF) membrane (Bio-Rad, City, State, USA) by
electroblotting at 100V in Tris/Glycine SDS buffer for 1 hour. Nonspecific binding sites
were blocked with 50 mM Tris buffered saline, 2.7 mM KCl, 138m M NaCl, 0.5% (v/v)
Tween®20 (TBST) and 5% (w/v) non-fat dry milk (NFDM). The membrane was then
treated with M2 Anti-Flag antibody (Sigma-Aldrich, St. Louis, MO, USA) (1:2000 in
TBST + 3% NFDM) and horseradish peroxidase conjugated goat anti-mouse IgG
antibody (Sigma-Aldrich, St. Louis, MO, USA) (1:5000 in TBST + 3 % NFDM).
Finally, SuperSignal Pico West chemiluminescent substrate (ThermoScientific, Rockford,
IL, USA) allowed for chemiluminescence detection using a Luminary imaging system
(Fotodyne, Hartland, WI, USA).
All enzyme activity assays were performed with CCM that had been quantified at
least twice by Western blot analysis. First, a scanning Western blot was run with varying
dilutions of the CCM to assess the differences in the amounts of protein that could arise
due to differing expression levels of mutants. Based on the results of the first Western
blot, all samples were diluted to the same concentration and were verified by a second
independent immunoblot. To quantify the amounts of protein expressed for each sample,
a known concentration of the carboxy-terminal FLAG-BAP fusion protein (Sigma
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Aldrich, St. Louis, MO, USA) was included on the second Western blot as a standard. All
protein bands were normalized relative to the FLAG-BAP standard using the TotalLab
software program in conjunction with the Luminary imager (Fotodyne, Hartland, WI,
USA).

4.3.6

Assay of NPP7 catalytic activity
Fluorescence-based assay: Hydrolysis of LPC, PAF and SM by NPP7 was

monitored using a modification of Invitrogen’s Amplex® Red phosphatidylcholinespecific phospholipase C assay kit (Invitrogen, Carlsbad, CA, USA). NPP7 assay buffer
was prepared as previously described (containing 50 mM tris-HCl, pH 8.0, 150 mM
NaCl, and 10mM taurocholic acid (Nyberg et al. 1996). Unlike the previous work of
Nyberg et al. we have determined that EDTA is an inhibitor of the hydrolytic activity of
NPP7ExFLAG as one would expect for a metalloenzyme (Wanjala et al., manuscript in
preparation). Each well on a 96-well plate (half area, Corning, City State, USA) was
loaded with a total of 60 µL consisting of 20 µL each of substrate, Amplex Red cocktail
(10 μM Amplex Red reagent, 0.1 U/ml choline oxidase, 1 U/ml horseradish peroxidase, 4
U/ml alkaline phosphatase) and normalized concentrations of enzyme diluted from CCM.
The activity of wild type NPP7ExFLAG or mutants was determined by monitoring
fluorescence (excitation 571 nm and emission 585 nm) every minute for two hours using
a Synergy 2 multi-well plate reader (BioTek, Winooski, VT, USA).
Absorbance-based activity assay: Hydrolysis of pNPPC as a function of
NPP7ExFLAG activity was monitored via an absorbance assay based on the generation
of para-nitrophenolate. This hydrolytic product has a maximum absorption at 405 nm.
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Each well of a 96 well plate (half area, Corning, City State, USA) was loaded with a total
of 60 µl consisting of NPP7 assay buffer, 400 µM of substrate and normalized amounts
of enzyme from CCM. Wild type NPP7ExFLAG or mutant activity was monitored by
measuring absorbance at 405 nm every minute for two hours using a Synergy 2 multiwell plate reader (BioTek, Winooski, VT, USA).
Dose response assays were run with varying substrate concentrations using the
fluorescence-based (LPC, PAF, SM) or the absorbance-based assay (pNPPC). Relative
fluorescence or absorbance units were converted to product concentrations using standard
curves. For the fluorescence assay, varying concentrations of resorufin (the ultimate
fluorescent product) were used to monitor the level of fluorescence in the presence of all
other assay components with the exception of NPP7ExFLAG to generate a standard
curve. For the absorbance assay, varying concentrations of para-nitrophenol were used in
the presence of all other assay components with the exception of NPP7ExFLAG to obtain
absorbance values at 405 nm for the standard curve. The trend line equations from these
calibration curves were generated using Microsoft Excel (2007) and were used to convert
all relative fluorescence and absorbance units to product concentrations. Initial rates for
all reactions were determined from the slopes of the linear ranges in the product versus
time plots. Curve fitting on Michaelis-Menten initial rate versus substrate concentration
plots was done using the KaleidaGraph 4.0 software package (Synergy software,
Reading, PA, USA) data was fitted to the following equation y = m1 x m2x(1+ m2x) (Km
= 1/m2 and Vmax = m2). The catalytic constant (kcat) was calculated by dividing Vmax by
the enzyme concentration used in all assays.
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4.4

Results

4.4.1

Generation of the NPP7 homology model
Fig. 4.1 shows the energy minimized NPP7 homology model obtained using the

Xac crystal structure, PDB (Berman et al. 2000) entry 2gso (Zalatan et al. 2006), as
template. The white circle highlights our designated binding pocket, an 8Å radius around
the active site residue, threonine 75. The 8Å radius was selected because it was large
enough to accommodate the polar headgroup of the large lipid substrates hydrolyzed by
NPP7. In close proximity to the active residue are two divalent metal cations transferred
directly from the Xac template. Like all NPP isoforms, NPP7 requires divalent metal
cations for its phosphodiesterase activity.The resulting NPP7 homology model displayed
strong interactions between known metal ion coordinating residues (Asp 39, Asp 199, His
203, Asp 246, His 247, His 353) and the two zinc ions (see Fig. 4.2). All six of these
residues are approximately 2Å away from one of the metals in the refined model.
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8Å

Fig. 4.1. NPP7 homology model. The homology model was generated in MOE
using the general bacterial Xac NPP crystal structure (PDB entry 2GSO) as the
modeling template and human NPP7 nucleotide sequence (Genbank Id AY20633)
as the modeling target. The white circle highlights the proposed phosphate target
area within the NPP7 active site, an 8Å radius around the active residue
threonine75, which is shown as a space filling model. Residues shown in stick
models were identified as outliers by the Ramachandran plot.
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M2

M1

Fig. 4.2. NPP7 homology model metal coordination sites. In close proximity to the
active site residue threonine 75 are two divalent metal cations speculated to be present
in NPP7 that result from homology modeling based on the Xac template. Each metal
coordinating residue is approximately 2Ǻ away from the metal it coordinates

4.4.2

Substrate docking
Fig. 4.3 shows the results of stepwise docking for each of the three previously

identified lysolipid substrates of NPP7. All three choline groups are in close proximity
and all phosphate groups docked within the same vicinity. However, as one might
reasonably expect due to the weaker, non-directional van der Waals interactions, the
hydrophobic chains adopted different positions. Since there are no structural differences
in the hydrophobic chains of the three substrates, we manually placed the chains for LPC
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and SM to follow the same shape as that of PAF. Energy minimizing these manually
created poses gave conformations with drastically reduced energies and moved the
common groups closer. Fig. 4.3 shows a superposition of these conformations which
were used for analyzing interactions.

A

B

Choline
groups
PO3
groups

T75

SM sphingoid
tail

R
R’
R

R

Palmitate
tails
Color Code
Blue – SM
Green – LPC
Gold – PAF
White - pNPPC

R = C15H31 , R’ = C13H27

Fig. 4.3. Final docked conformations for LPC, PAF, SM and pNPPC in human
NPP7. Minimized poses of all substrates have significant overlap within the active site.
All common groups on different substrates are located within close proximity (A). The
lipid substrates have a common basic structure whereas pNPPC is quite different (B) but
the phosphocholine head groups for all docked in the same area.
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4.4.3

Analysis of protein-substrate interactions
Table 4.2 summarizes the predictions made from the complexes of all docked

substrates with the human NPP7 homology model. The left column lists all residues
within 4.5 Å of each substrate. It is noteworthy that the same residues were identified for
most substrates since their common functional groups were located within close
proximity. Only the second hydrophobic tail of SM gave unique interacting residues.
Residues selected for mutation after analyzing the types and distances of predicted
interactions are shown. Predicted effects on enzyme activity based on these interactions
are included.

Table 4.2 Modeled substrate interactions with NPP7.
Interactions

Proposed
Mutation

LPC/SM/PAF
palmitate tail
F80, H110, W119,
F141, Y142, P143,
Y166

F80A
Y142A
Y166A

Choline group
N96, L107, H203,
F275

F275A
L107F

SM sphingoid tail
F141, N168, E169,
W172, Y194, F195,
E19

E169A
E169Q

Interaction Distance (Å)
LPC

PAF

SM

3.9
8.2
4.0

3.9
8.2
4.0

3.5
8.4
3. 9

4.3, 3.8 4.3, 3.6 4.7, 4.0
3.4, 4.0
4.0
5.3

5.9
5.9

3.2
3.2
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3.2, 3.9
3.2, 3.9

Predicted Effect of
Mutation

Lose VDW, decrease
activity
Minimal effect
Lose VDW, decrease
activity
Lose +/π, decrease
activity
Gain +/π, slightly
enhanced
SM: Lose H-bond,
decrease activity
Eliminate negative
charged side chain Increase activity

4.4.4

Effect of mutations on the hydrolysis of LPC
Fig. 4.4 shows the lowest energy docked conformation of LPC16:0 (shown in

white ball and stick) in the NPP7 active site with mutated residues displayed as stick. All
mutants of residues colored green hydrolyzed LPC (16:0) with a higher overall k cat/Km
than wild type NPP7ExFLAG enzyme. Mutants of the residues colored red hydrolyzed
LPC16:0 with a lower k cat/Km than did wild type NPP7ExFLAG. All kinetic parameters
obtained from activity assays are presented in Table 4.3. Wild type NPP7ExFLAG had an
apparent Vmax of 2.5 μM/sec and a kcat value of 2.9 sec-1. Three mutants (F80A, Y166A
and E169A) displayed lower Vmax and kcat values than the wild type enzyme. These
mutants also exhibited a lower affinity for LPC16:0 as seen from their K m values which
are all higher than that of wild type enzyme. Accordingly, their k cat/Km values are lower
than the wild type enzyme. In the model, F80 and Y166 are located 4Å or less from the
nonpolar palmitate chain of LPC. Mutation to the smaller alanine residue would increase
this contact distance and was predicted to have a detrimental effect on enzyme function
(Table 4.2). In contrast, E169 is located almost 6Å from the polar glycerol backbone of
LPC, and mutation was not predicted to have a detrimental impact on hydrolysis of this
substrate. This apparent contradiction (especially with E169A mutation) between
modeling predictions and experimental results might be mitigated if a water-bridged
interaction occurs as water molecules were not included in these gas-phase docking
studies. One mutant (F275A) had no observable catalytic activity against LPC16:0. This
residue is located less than 4.5Å from the choline headgroup of LPC, and is oriented to
make a cation-pi interaction. Such an interaction is not possible in the alanine mutant,
consistent with the loss of activity upon mutation. Three mutants (L107F, Y142A and
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E169Q) exhibited higher Vmax and kcat values than the wild type enzyme. Interestingly,
these three mutants also had higher Km values than the wild type enzyme. The
combination of these values gives L107F a higher kcat/Km value while giving E169Q a
lower kcat/Km value than wild type enzyme. In the model L107 is located 3.5 Å from the
methyl of LPC choline group and 3.99 Å from the palmitate tail where it would
potentially have hydrophobic interactions with both LPC regions. Mutation to a
phenylanine introduces a phenyl ring with a favorable pi cloud to potentially form a
cation-pi interaction with the positively charged LPC choline group and stronger
hydrophobic interactions with the palmitate tail than the leucine. This led to the observed
increase in catalytic activity of the L107F mutant as was computationally predicted.
Y142 was selected as a control mutation site as it is located too far away from any of the
substrates to have an effect on their hydrolysis. It is located 8.2 Å away from LPC
palmitate tail (the closest interaction point). The unexpected results of an increase in V max
with an alanine replacement may be due to an allosteric effect that led to better and faster
product release. The increase in the K m value however, led to a kcat/Km value similar to
that of the wild type enzyme as predicted by the model. As noted previously, E169 is
located about 6 Å away from the hydroxyl group on the polar glycerol backbone of LPC
and its replacement with a glutamine led to a minimal effect in contrast to an alanine
replacement. This result further indicates the possibility of a water-bridged interaction
which was maintained with a glutamine replacement though the interaction would be
weaker than with a glutamate, hence the slight decrease in k cat/Km.
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LPC

Fig. 4.4. LPC docked into the NPP7 homology model. LPC (16:0) is shown as
white ball and stick. Only mutated residues are shown (sticks) with mutation sites that
increased kcat/Km in green and those that decreased kcat/Km in red. The distance (Å) of
each residue from the closest interaction point on the substrate is also shown.
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Table 4.3 Kinetic parameters for hydrolysis of LPC 16:0.
Enzyme

Km (μM)

Vmax (μM/sec) (x 10-2)

kcat(sec-1)

kcat/Km (M-1sec-1) (x 104)

L107F

61 ± 2.8

3.5 ± 0.03

4.2 ± 0.03

6.8 ± 1.6

Y142A

69 ± 0.9

3.0 ± 0.01

3.6 ± 0.01

5.2 ± 0.05

Wild type

57 ± 0.7

2.5 ± 0.01

2.9 ± 0.01

5.1 ± 0.1

E169Q

88 ± 6.8

3.3 ± 0.02

3.8 ± 0.03

4.3 ± 0.4

E169A

100 ± 15

1.0 ± 0.04

1.2 ± 0.05

1.2 ± 0.2

F80A

120 ± 3.0

0.7 ± 0.01

1.4 ± 0.01

1.2 ± 0.3

Y166A

100 ± 5.0

0.9 ± 0.03

1.1 ± 0.03

1.0 ± 0.2

F275A

No activity

4.4.5

Effect of mutations on hydrolysis of PAF
Fig. 4.5 shows the lowest energy docked conformation of PAF16:0 (shown in

gold ball and stick) in the NPP7 active site with mutated residues displayed as stick. All
mutants of residues shown in green hydrolyzed LPC (16:0) with a higher overall kcat/Km
than wild type NPP7ExFLAG enzyme. Mutants of the residues shown in red hydrolyzed
LPC16:0 at a lower kcat/Km than did NPP7ExFLAG. All kinetic parameters obtained
from activity assays are presented in Table 4.4. Wild type NPP7ExFLAG had an apparent
Vmax of 1.3 μM/sec and a kcat value of 1.6 sec-1. Three mutants (F80A, Y166A and
E169A) exhibited slightly lower Vmax and kcat values and higher Km values than the wild
type enzyme. Accordingly, these substrates also had lower specificities for the substrate
as seen from their kcat/Km values. In the model, F80 and Y166 are both less than 4 Å from
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the non polar palmitate chain of PAF16:0. As for LPC, mutation to the smaller alanine
residue would increase these contact distances and was predicted to have a detrimental
effect on enzyme function (Table 4.2). Unlike LPC, E169 is located 3.15 Å from the
acetyl group of PAF, and mutation was not predicted to have a detrimental impact on
hydrolysis of this substrate due to a possible unfavorable interaction between the
hydrophobic methyl group (on PAF acetyl group) and the polar side chain of E169. The
possibility of a water-bridged interaction between E169 and the polar oxygen atoms on
PAF could again mitigate this apparent contradiction between modeling predictions and
experimental results. One mutant (F275A) had no observable catalytic activity against
PAF16:0. As for LPC, this residue is located less than 4.5 Å from the choline head group
of PAF16:0, and is oriented to make a cation-pi interaction. Such an interaction is not
possible in the alanine mutant, consistent with the loss of activity upon mutation. Three
mutants (L107F, Y142A and E169Q) exhibited higher Vmax and kcat values than the wild
type enzyme. L107F and E169Q also had higher K m values but L107F also had a much
higher Vmax (thus kcat) value that led to a k cat/Km value above that of the wild type
enzyme. In contrast E169Q had a higher Km value that led to a lower specificity constant
than that of wild type enzyme. Y142A had a lower K m value than that of wild type
enzyme and this combined with the higher k cat value led to a kcat/Km value higher than
that of wild type enzyme. The L107F, Y142A and E169Q effects can be similarly
explained as in the case of LPC.
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PAF

Fig. 4.5. PAF docked into the NPP7 active site. PAF (16:0) is shown as gold ball and
stick. Only mutated residues are shown (sticks) with those that increased kcat/Km in
green and those that decreased kcat/Km in red. The distance (Å) of each residue from the
closest interaction point on the substrate is also shown.
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Table 4.4 Kinetic parameters for hydrolysis of PAF16:0.
Enzyme

Km (μM)

Vmax (μM/sec)(x 10-2)

Y142A

75 ± 2

2.0 ± 0.03

2.5 ± 0.04

3.3 ± 0.6

L107F

94 ± 3

2.4 ± 0.3

2.9 ± 0.3

3.1 ± 0.2

Wild type

82 ± 2

1.3 ± 0.02

1.6 ± 0.02

2.0 ± 0.8

E169Q

130 ± 8

1.9 ± 0.1

2.3 ± 0.2

1.7 ± 0.2

F80A

120 ± 3

1.2 ± 0.03

1.4 ± 0.03

1.2 ± 0.4

E169A

95 ± 6

0.8 ± 0.02

0.80 ± 0.02

1.0 ± 0.2

Y166A

200 ± 10

0.7 ± 0.02

0.80 ± 0.04

0.4 ± 0.2

F275A

4.4.6

kcat (sec-1) kcat/Km (M-1sec-1) (x 104)

Not enough activity to study kinetics

Effect of mutations on hydrolysis of SM
Fig. 4.6 shows the lowest energy docked conformation of SM (shown in blue ball

and stick) in the NPP7 active site with mutated residues displayed as stick. Mutants of
residues colored green hydrolyzed SM with a higher overall kcat/Km than wild type
NPP7ExFLAG. Mutants of residues colored red hydrolyzed SM at a lower kcat/Km than
did NPP7ExFLAG. Residue E169 is colored partially red and partially green because
two mutations were made and each had an opposite effect compared to the wild type
enzyme. All kinetic parameters obtained from activity assays are presented in Table 4.5.
Wild type NPP7ExFLAG had an apparent Vmax of 3.0 μM/sec and a kcat value of 3.7 sec1

. Four mutants (F80A, Y166A, E169A and F275A) exhibited lower Vmax and kcat values

than the wild type enzyme. Interestingly, all these mutants exhibited lower K m (14 μM for
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F80A, 17 μM for E169A and 12 μM for F275A and Y166A) values meaning they bound
SM better than the wild type enzyme (23 μM). However, E169A and F275A had lower
kcat/Km values due to their much more reduced k cat values. These two mutants bound SM
more tightly than wild type enzyme but were the least efficient in converting the substrate
to product as seen from the drastically reduced k cat/Km values. F80A had a k cat/Km value
slightly higher than that of wild type enzyme. In the model, F80 and Y166 are located 4
Å or less from the non polar sphingoid chain of SM. Mutation to the smaller alanine
residue would increase this contact distance and was predicted to have a detrimental
effect on enzyme function (Table 4.2). F275 is about 4 Å away from the choline group of
SM and its mutation to an alanine was predicted to have detrimental effects due to
elimination of a cation-pi interaction. The results obtained match this prediction but the
low Km value was unexpected and indicates that the change led to better binding affinity
for SM but without generation of much product. E169 was closer to the sphingoid chain
(second hydrophobic chain) chain of SM and evidently has a hydrogen bond with a
hydroxyl group on the substrate. Replacement of the glutamate with an alanine
eliminated this hydrogen bond and led to the observed reduction in hydrolysis. Three
other mutants (Y142A, Y166A and E169Q) exhibited Vmax and kcat values that were
essentially similar to the wild type enzyme. Of these, Y142A had a Km value twice that of
wild type enzyme meaning it had half the binding affinity compared to that of wild type
enzyme for SM while Y166A and E169Q had reduced K m values and accordingly
exhibited higher specificities for the substrate (about 2.5 x 10 5 M-1 sec-1) compared to that
of wild type enzyme (1.6 x 10 5 M-1 sec-1 ). In the model, L107 is less than 4.5 Å from the
interaction sites with SM (choline head group and sphingoid chain). Its change to the
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larger, more hydrophobic phenylanine improved the van der Waal’s interactions with the
palmitate chain and introduced a cation-pi interaction with the choline head group leading
to the observed increase in the Vmax and kcat values for SM hydrolysis by L107F.
However, the higher Km and kcat/Km values indicate poorer binding and lower specificity
for the substrate and this is probably because the larger phenylanine residue reduced the
space needed for the bulky SM substrate. In the model, Both Y166 and E169 are within
less than 4 Å of the hydrophobic chains of SM. They both had drastically reduced K m
values that led to higher k cat/Km values. Changing Y166 to alanine may have allowed SM
to better fit into the binding pocket and hence the reduced K m value. Replacing E169 with
a glutamine replaced a negatively charged side chain with an uncharged amide side chain
close to the hydrophobic portion of the substrate leading to better binding because the
hydrogen bond was retained with the glutamine in place of a glutamate.
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SM

Sphingoid
chain

Palmitate
chain

Fig. 4.6. SM docked into the NPP7 active site. SM is shown as blue ball and
stick. All mutation points are shown with those that increased kcat/Km in green and
those that decreased kcat/Km in red. The distance (Å) of each residue from the
closest interaction point on the substrate is also shown.
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Table 4.5 Kinetic parameters for hydrolysis of SM.
Enzyme

Km (μM) Vmax (μM/sec) (x 10-2)

kcat (sec-1)

kcat/Km (M-1sec-1) (x 104)

E169Q

15 ± 5

3.2 ± 0.08

3.8 ± 0.1

25.0 ± 6.0

Y166A

12 ± 0.4

2.6 ± 0.01

3.1 ± 0.2

25.8 ± 5.0

F80A

14 ± 6

2.2 ± 0.3

2.6 ± 0.3

18.6 ± 5.0

Wild type

23 ± 3

3.0 ± 0.1

3.7 ± 0.2

16.5 ± 4.0

E169A

17 ± 2

1.8 ± 0.1

2.2 ± 0.2

11.6 ± 2.0

L107F

37 ± 3

3.5 ± 0.1

4.2 ± 0.1

11.4 ± 4.0

Y142A

47 ± 7

3.1 ± 0.2

3.7 ± 0.2

7.9 ± 3.0

F275A

12 ± 1

0.7 ± 0.1

0.9 ± 0.2

7.5 ± 2.0

4.4.7

Effect of mutations on hydrolysis of pNPPC
Fig. 4.10 shows the lowest energy docked conformation of pNPPC (shown in

yellow ball and stick) in the NPP7 active site with mutated residues displayed as stick.
Mutants of residues colored green hydrolyzed pNPPC with a higher kcat/Km than the wild
type NPP7ExFLAG enzyme. Mutants of residues colored red hydrolyzed pNPPC at a
lower kcat/Km than did NPP7ExFLAG. Residue E169 is left in natural element colors
because two mutations were made and each had an opposite effect compared to the wild
type enzyme. All kinetic parameters obtained from activity assays are presented in Table
4.6. Wild type NPP7ExFLAG had an apparent Vmax of 1.1 μM/sec and a kcat value of 1.4
sec-1. Four mutants (F80A, Y166A, E169A and F275A) exhibited lower Vmax and kcat
values, as well as higher Km values, and accordingly had lower specificities than the wild
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type enzyme. From the model, F80 and Y166 are too far away from the substrate and
were predicted not to have effects when mutated to alanine. The contradictory effects
may indicate that their mutations led to allosteric effects that affected recognition of this
substrate. It is also possible that this model did not correctly depict pNPPC since we
emphasized mostly the three natural substrates that were known at the time the model
was generated. Two mutants (L107F and Y142A) exhibited Vmax and kcat values above
those obtained with the wild type enzyme. L107F also had a slightly lower Km value than
that of wild type enzyme and thus a higher k cat/Km value for pNPPC. Y142A on the other
hand had a higher Km value than wild type enzyme but similar specificity constant due to
an improved kcat value. In the model, L107F less than 4.5 Å away from the choline
headgroup of pNPPC and thus its mutation to a phenylanine introduced a cation-pi
interaction yielding the expected effects. Y142A was too far away and its effects here, as
with the other substrates, were minimal. One mutant (E169Q) had Vmax and kcat values
similar to those obtained with wild type enzyme and as seen from the model, E169 is
located about 6 Å away from the substrate and its mutation was accordingly predicted to
have minimal effect.
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pNPPC

Red – reduced activity
Green – increased activity

Fig. 4.7. pNPPC docked into the NPP7 active site. pNPPC is shown as yellow
ball and stick. Only mutated residues are shown (sticks) with those that increased
kcat/Km in green and those that decreased kcat/Km in red. The distance (Å) of each
residue from the closest interaction point on the substrate is also shown.
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Table 4.6 Kinetic parameters for hydrolysis of pNPPC.
Enzyme
L107F
Wild type
Y142A
F80A
E169A
E169Q
Y166A
F275A

4.5

Km (μM)

Vmax (μM/sec) (x 10-2)

kcat (sec-1)

kcat/Km (sec-1 M-1) (x 104)

310 ± 5.0

1.4 ± 0.05

1.7 ± 0.1

0.60 ± 0.02

360 ± 8.0

1.1 ± 0.01

1.4 ± 0.1

0.40 ± 0.03

400 ± 4.0

1.4 ± 0.01

1.7 ± 0.1

0.40 ± 0.02

450 ± 10.0

0.63 ± 0.04

0.8 ± 0.1

0.20 ± 0.1

170 ± 30.0

0.42 ± 0.03

0.5 ± 0.03

0.30 ± 0.02

440 ± 5.0

1.2 ± 0.02

1.4 ± 0.1

0.30 ± 0.02

820 ± 20.0

0.62 ± 0.03

0.7 ± 0.04

0.09 ± 0.01

120 ± 5.0

0.23 ± 0.03

0.3 ± 0.03

0.03 ± 0.01

Discussion
NPP enzymes have been reported to possess well-defined substrate specificity but

it is not known what determines this property (Stefan et al., 2005). Separate substrate
recognition surveys have been performed for NPP2 (Clair et al. 2003) and NPP6
(Sakagami et al. 2005) and established the ability of these two phosphodiesterases to
discriminate between substrates with very small structural variations. For instance NPP2
hydrolyzes LPC and SPC but not PAF. Likewise, NPP6 readily recognizes and
hydrolyzes LPC and lysoPAF but not PAF. We recently conducted a detailed survey of
substrate recognition by NPP7 and identified lysoPAF and SPC as endogenous
phospholipid substrates in addition to the previously known LPC, PAF and SM. These
findings made NPP7 the only NPP isoform that has the ability to hydrolyze lipids with
84

one or two long hydrophobic tails. In this study, we have used molecular modeling and
experimental mutagenesis to identify and characterize amino acid residues that determine
NPP7 substrate recognition. We have further used experimental mutagenesis to validate
these computational results and characterize the role of each identified residue in
determining NPP7 substrate recognition and preferences.
The use of homology modeling to study NPP7 is a challenging task and has not
been previously reported likely because none of the NPP isoforms have a publicly
available solved crystal structure. The only crystal structure currently available is the
bacterial Xac NPP (Zalatan et al., 2005) structure which was found to share 34% identity
with human NPP7. Experimental validation of the modeling predictions was therefore an
important aspect of this study. Results for the hydrolysis of LPC16:0 show a match with
computational predictions for all predicted amino acids with the exception of E169A
which led to an unexpected decrease in k cat/Km. However, this discrepancy can be
logically mitigated if there exists a water-bridged interaction between the residue E169
and the polar glycerol backbone of LPC16:0 since water molecules were not including in
our modeling system. This fact is further reinforced by the E169Q mutation which led to
only a small decrease in k cat/Km value. The glutamine replacement in this case retained
the ability to hydrogen bond (water-bridged) with the glycerol backbone of LPC16:0
although to a lesser extent than a glutamate would. The Y142A mutant had a k cat/Km
value that was essentially the same as that of the wild type enzyme. This was
computationally expected as this residue was approximately 8 Å away from the possible
interaction point with LPC. The modeling predictions with residues F80A, Y166A,
E169A and F275A having a reduction in catalytic function (increased K m, reduced Vmax,
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kcat and kcat/Km) and L107F having an overall increase in function (although with a slight
increase in Km value) were experimentally observed. All computational predictions for
the hydrolysis of PAF16:0 were matched by experimental results with all mutants except
for Y142A. The contradictory results in the case of Y142A with PAF16:0 could be due to
an allosteric effect that led to faster product generation even with lower substrate affinity
than the wild type enzyme. With both substrates, there was an increase in the K m value
with mutations that generally led to improved Vmax and kcat values probably because of
minimally altered folding of the protein. Ultimately, the experimental results for
hydrolysis of LPC16:0 and PAF16:0 show that the homology model and the predictions
made from it are valid and we can therefore conclude that LPC16:0 and PAF16:0 occupy
a common binding pocket within the active site of NPP7.
The effects on the hydrolysis of SM were significantly different compared to
LPC16:0 and PAF16:0. Y166A, one of the three mutations that had detrimental effects on
hydrolysis of LPC16:0 and PAF16:0 had a significant enhancement in the hydrolysis of
SM. This contradiction in computational predictions and experimental results is likely
due to the bulky size of SM which which necessarily requires more space to fit within the
NPP7 active site. This explains the positive effect observed when the larger tyrosine 166
residue is replaced with a much smaller alanine residue. L107F, which led to an increase
in hydrolysis of LPC16:0 and PAF16:0 as was predicted by modeling, only slightly
increased the Vmax and kcat against SM but also increased the K m value, leading to lower
specificity for this substrate. This also can be explained if the bulky size of SM is
considered. The smaller L107 residue was replaced by a much larger phenylalanine that
could be sterically unfavorable for SM binding. This indicates that SM may not bind in
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exactly the same binding pocket as LPC16:0 and PAF16:0 or that the residues selected do
not interact with SM as they do with LPC and PAF. Another interesting mutation site
with regard to SM hydrolysis was E169. E169A led to a significant reduction in all
kinetic parameters except Km whereas E169Q led to a significant decrease in K m and an
increase in Vmax, kcat, and kcat/Km values leading to an overall better catalytic function of
E169Q than the wild type. Effects observed for both of these mutations clearly indicate
the importance of this site in the recognition of SM by NPP7. The drastic reduction in
performance with the E169A mutation is evidence of elimination of the important
hydrogen bond between E169 and SM (Figure 4.6). The significant improvement in
performance with the E169Q is evidence not only of the H-bond between glutamine and
SM but also of the improved electrostatic interactions when a negatively charged side
chain (E169) was replaced with a neutral residue (Q169). E169 mutants had the largest
effect on hydrolysis of SM compared to the other mutants made and since SM is
currently the only substrate with two long hydrophobic chains, we can conclude that the
second chain of SM plays an essential role in its recognition by NPP7. The reversal in
effects on hydrolysis of SM with majority of the mutants in comparison to hydrolysis of
the other substrates is a strong indication that the manual manipulation of the palmitate
chain led to a biased model of SM and more refinement needs to be done in the future to
identify the exact binding pocket for this substrate.
Para-nitrophenylphosphorylcholine (pNPPC) is a synthetic compound recently
identified as a substrate for NPP7. It is much smaller in size than the three known lipid
substrates with much lower degree of flexibility. The mutants made were mainly based
on the docking results of the three lipid substrates but experiments run with pNPPC
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showed that mostof computational predictions were matched by experimental results.
This indicates that pNPPC, PAF and LPC, all bind in a common binding pocket within
the NPP7 active site. However the model for pNPPC needs refinement as some the
mutations had unexpected effects although they matched those of PAF and LPC. In its
current conformation (Fig. 4.7), residues F80 and Y166 are located more than 10Å away
from pNPPC but experimentally had a significant reduction in overall performance of the
enzyme. This indicates that pNPPC binds in the same pocket as LPC and PAF but may
do so with a different conformation than that shown in the model to account for the
mutation effects.
To identify substrate-binding determinants, the magnitude and/or direction of
effect of each mutation was compared for the different substrates. Fig. 4.8 summarizes
the kcat/ Km values for each mutant normalized to that of wild type against the same
substrate. Out of all the mutations made, only F275A led to loss of activity against some
of the substrates (LPC and PAF) and retained minimal activity against SM and pNPPC.
This residue was predicted to make a cation/pi interaction with the choline groups of all
substrates tested. It would have been interesting to investigate its effects on a substrate
without a choline head group but unfortunately, all currently known substrates for NPP7
have this common functional group. Y166A led to large reduction in recognition of LPC,
PAF and pNPPC (reduced k cat/Km values) but increased SM recognition (increased
kcat/Km value). Since SM is bulkier than all the other three substrates, the replacement of
Y166 with an alanine may have allowed more space to accommodate substrate in the
binding pocket. These data show that Y166 is important in LPC, PAF and pNPPC
recognition but not in the recognition of SM by NPP7. Conversely, L107F led to a
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significant increase in k cat /Km of PAF, LPC and pNPPC but reduced the k cat/Km for SM
indicating that L107 is important for SM recognition but probably not as essential for the
recognition of the other three substrates.

1.8
1.6
1.4

Relative kcat/Km

1.2
1.0

0.8
0.6
0.4
0.2
0.0
L107F

Y142A

WT

E169Q

E169A

F80A

Y166A

F275A

Mutation

Fig. 4.8. Relative kcat/K m values of all mutants for hydrolysis of all substrates,
LPC (white bars), PAF16:0 (light grey bars), pNPPC (dark grey bars and SM
(black bars). The relative kcat/Km values were obtained by dividing the K m value of
each mutant with that of wild type enzyme against the same substrate.

To analyze substrate specifying determinants for NPP7 as opposed to other NPP
isoforms, an alignment of the amino acid sequences of all NPP enzymes was done and
the residues in other NPP isoforms that aligned with the NPP7 mutation sites were
identified as shown in Table 4.5. An interesting observation is that three (F80, L107, and
Y142,) of the six NPP7 mutation sites identified by computational modeling were
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Table 4.7 NPP7 mutation sites aligned with all human NPP isoforms
Isoform

Active site

Mutation site

NPP7

T75

F80A

L107F

NPP6

S71

Y76

F103

W139

D163

F166

Q265

NPP5

T72

Y77

F104

W139

F163

R166

T262

NPP4

T70

Y75

F102

W136

F160

R163

T261

NPP3

T205

Y210

F237

W271

F295

R298

F396

NPP2

T210

Y215

F242

W276

H282

R285

I435

NPP1

T256

Y261

F288

W322

F346

R349

I446

Y142A Y166A E169A/Q F275A

conserved in all other NPPs but were different in NPP7. Additionally, one residue
(E169) was a conserved arginine in all NPPs except NPP6 which had a phenylanine.
Only one mutation (L107F) was changed to the residue in the other NPP isoforms and
experimental results indicate its importance in SM recognition. NPP7 is the only NPP
enzyme that hydrolyzes SM. From Table 4.5, we can conclude that L107 and E169
provide for the specificity for SM by NPP7. In place of E169, NPP6 has a phenylalanine
while the other five isoforms contain an arginine. Both phenylalanine and arginine are
much bulkier than the glutamate in NPP7 which further accounts for the ability of NPP7
to bind this larger substrate that is not recognized by NPP2 and NPP6. Mutation of the
other five NPP7 mutation sites to those aligned in other isoforms may shed more light on
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specificity among these enzymes. It would be interesting to see if F166E and R285E can
lead to SM recognition by NPP6 and NPP2, respectively.
In conclusion, this work is the first of its kind where homology modeling has been
used to study structure-activity relationships in the NPP7. Although the template used
had only 34% amino acid identity with the NPP7 target sequence, validation results have
proved the model valid and helped analyze NPP7substrate recognition elements.
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CHAPTER 5

THE ROLE OF DIVALENT METAL CATIONS IN NPP7

5.1

Introduction
Like all known NPP isoforms, NPP7 is presumed to be a metalloenzyme that

depends on the presence of specific divalent metal cations for its catalytic function (1, 2).
The catalytic cycle for the seven known NPP enzymes has been described based on that
of the related and well studied phospho- and sulfo-coordinating enzymes which includes
the alkaline phosphatase superfamily (3, 4). Here we describe the use of circular
dichroism spectroscopy and enzyme activity determination to investigate whether the
active site divalent metal cations play solely functional or a combined structural and
functional role in NPP7. Our results show that these active site divalent metal cations
play only a functional role in this isoform. These experiments were performed in parallel
with the NPP2 and NPP6 isoforms as part of a comparative survey. Similar results were
obtained for all three isoforms studied, thus similar conclusions were reached concerning
the functional role of divalent cations in these related isoforms. Here the focus will be on
studies of NPP7 with discussion of those pertaining to NPP2 and NPP6 when appropriate.
The comparative survey, in its entirety, is a manuscript co-authored by Truc Chi T. Pham,
Irene W. Wanjala, Angela, L. Howard, Abby L. Parill, and Daniel L. Baker which is to be
submitted to the Biochemical Journal.
Previously published data suggested that the catalytic activity of NPP7 was
inhibited by the presence of 0.25 mM zinc cations and that this inhibitory effect was
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prevented by the addition of 2 mM ethylene diaminetetraacetic acid (EDTA) (1). These
findings are hard to rationalize based on the fact that NPP7, like all NPP isoforms, is a
metalloenzyme that requires divalent metal cations for catalytic function (2-5). As part of
a comparative analysis to determine the role (structural and/ or functional) of divalent
metal cations in the three known lysophospholipid preferring NPP isoforms, NPP2,
NPP6, and NPP7, experiments detailing the effect of divalent metal ions on the structure
and function of NPP7 were performed. Results indicated that all three NPP isoforms are
inhibited by EDTA at an enzyme:EDTA molar ratio greator or equal to 1:120 and that the
addition of divalent metal cations (including cobalt, nickel and zinc for NPP7) to these
inactivated enzymes can restore most of the lost activity. We also show that neither
EDTA (which inhibited the enzyme) nor the divalent metal cations (which restored
enzyme activity) altered the secondary structure of the enzyme.

5.2

Experimental Design

5.2.1

EDTA treatment
Human NPP7ExFLAG protein was expressed and purified using the baculovirus-

Sf9 insect cell system described in Chapter 2, sections 2.3.2-2.3.4. Affinity purified
protein was used with stock solutions of varying ETDA concentrations to generate
samples with increasing molar ratios of NPP7 protein to chelator (NPP7:EDTA ratios of
1:0, 1:1, 1:2, 1:4, 1:8, 1:20, and 1:120). To prepare these samples, equal volumes (5 μL)
of NPP7ExFLAG (8 μM) was mixed with EDTA stocks in CD buffer (10 mM Tris, 10
mM NaCl, pH 7.4) at 0 μM, 8 μM, 16 μM, 32 μM, 64 μM, 160 μM and 720 μM.
Duplicate samples were made for each EDTA treatment. One set of the samples was
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immediately incubated at 4 oC for 30 minutes while the other set was incubated for 16
hours. Following the incubation period, the catalytic activity of NPP7 was examined
using para-nitrophenylphosphocholine (pNPPC, Sigma-Aldrich, St. Louis, MO, USA) as
the substrate. NPP7ExFLAG:EDTA samples were diluted to an enzyme concentration of
30 nM in NPP7 assay buffer (50 mM Tris-HCl, 150 mM NaCl, 10mM sodium
taurocholate, pH 7.4) before addition onto the plate. Each reaction well contained a total
of 60 µL consisting of 20 µL each of 30 nM enzyme sample, 500 µM pNPPC and NPP7
assay buffer. In this activity assay, the absorbance of the para-nitrophenolate anion
product generated by the lysophospholipase C activity of NPP7 was monitored at 405 nm
every minute for a period of one hour using a Synergy-2 plate reader (BioTek, Winooski,
VT, USA). The relative responses of all enzyme/EDTA samples were determined at the
60th minute of the assay where responses were linear. All data were normalized to the
zero EDTA control.

5.2.2

Metal ion restoration
Samples containing NPP7ExFLAG and EDTA in a 1:120 molar ratio were

prepared by adding 10 μL of purified NPP7ExFLAG (6 μM) to 10 μL of EDTA solution
(720 μM). This mixture was incubated for 16 hours at 4 o C and diluted 1:100 with NPP7
assay buffer (50 mM tris-HCl, 150 mM NaCl, and 10mM sodium taurocholate, pH 7.4).
These working stocks contained 30 nM NPP7ExFLAG and 3.6 µM EDTA (maintaining
the 1:120 molar ratio). Solutions (30 mM) of divalent metal chlorides (Ca 2+, Co2+, Cu2+,
Fe2+, Mg2+, Mn2+, Ni2+, Zn2+) were prepared in NPP7 assay buffer. Equal volumes of the
enzyme:EDTA working stock were then combined with each metal chloride solution
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resulting in a solution with final enzyme:EDTA:metal molar ratios of 1:120:1 x 10 6 thus
constituting saturating amounts of EDTA compared to enzyme and metal cation
compared to EDTA. These mixtures were incubated at 4 oC for either 30 minutes or 16
hours. At the end of the incubation periods, the catalytic activity of the enzyme was
monitored as described using para-nitrophenylphosphocholine as substrate.

5.2.3

Structural studies using CD spectroscopy
To determine the effect of metal ion removal by EDTA treatment and of the

restoration of divalent metals on the secondary structure of NPP7ExFLAG, the following
sets of samples were prepared. First, NPP7ExFLAG (8 µM, 10 µL) was diluted with 10
µL of CD buffer (control sample). Second, additional samples were generated by mixing
NPP7ExFLAG (8 µM, 10 µL) with 10 µL of 960 µM EDTA in CD buffer, pH 7.4 (pH
7.0 for the Zn sample). All samples were incubated for 16 hours at 4°C. Addition of 280
µL of CD buffer to the control and one of the ETDA treated samples made up the
volumes to 300 µL that were analyzed for secondary structural compositions on a model
410 CD spectrophotometer (Aviv biomedical Inc., Lakewood, NJ, USA). Wavelength
scans were done at 25 °C from 190 to 260 nm in a 1 mm cuvet (zinc samples were
studied in 10 mm cuvettes). The 300 µL samples used for the wavelength scan were
diluted to 3 mL using CD buffer followed by CD thermal scans at 222 nm from 20 to 100
°C using a 10 mm cuvet. Metal treatment samples were prepared by diluting with 200 µL
of 200 mM stocks of CaCl2, CoCl2, or NiCl2 (instead of CD buffer used for controls) and
were incubated for either 30 minutes or 16 hours at 4°C. Wavelength and thermal scans
were then done as described previously for the control samples. Since Zn2+ readily
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formed insoluble Zn(OH) 2 at pH values higher than 7.0, all CD experiments in the
presence of Zn2+ were performed at pH 7.0. EDTA treated working stocks were prepared
as described previously with the exception that the CD buffer was pH 7.0 rather than pH
7.4 for the zinc-treated samples.

5.3

Results

5.3.1

EDTA treatment
Fig. 5.1 shows the effect of EDTA treatment on the activity of recombinant,

purified NPP7ExFLAG. Treatment of NPP7 with EDTA up to a 120 fold excess (30
minute incubation) showed ≥ 90% of the untreated enzyme activity using pNPPC as
substrate. Similarly, 16 hour incubation with molar ratios of EDTA lower than 1:20 had
little impact on enzyme activity. In contrast, 16 hours of exposure to EDTA at a 1:20
molar ratio decreased activity by approximately 30%, whereas EDTA treatment at a
1:120 molar ratio led to a reduction in activity of approximately 90% in NPP7ExFLAG
mediated hydrolysis of pNPPC.
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Fig. 5.1. The effect of EDTA on the catalytic activity of NPP7ExFLAG.
NPP7ExFLAG was treated with EDTA at various molar ratios of 1:0, 1:1, 1:2, 1:4,
1:8, 1:20, and 1:120 at 4oC for 30 minutes (white bars) or 16 hours (black bars).
Following dilution, the catalytic activity of NPP7ExFLAG was determined using
pNPPC as substrate.

5.3.2

Metal ion restoration
Sixteen hours of treatment with EDTA at a 1:120 molar ratio significantly

inhibited NPP7ExFLAG activity. We speculate this was due to the loss of one or more of
the required, active site divalent metals. To address whether this effect on enzyme
activity was reversible or not, divalent metals were added back to EDTA-treated
NPP7ExFLAG protein and enzymatic function was determined using pNPPC as
substrate. Fig. 5.2 shows that four (Ca2+, Co2+, Ni2+, and Zn2+) out of the seven divalent
metals tested restored activity of EDTA-treated NPP7ExFLAG above 20% within 30
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minutes. Cobalt treated NPP7ExFLAG had the greatest activityas compared to the
untreated control (118%), followed by Ni 2+ and Zn2+ at (65 and 79%), respectively. It is
interesting to note that the effect of Ca 2+ improved with additional incubation time to 16
hours, whereas the effect of Co 2+ and Ni 2+ did not change appreciably, whereas the effect
of Zn2+ decreased significantly. The decrease in activity with prolonged exposure was
reproducible but our experiments were not adequate to establish why this was the case.
Further research is is ongoing to investigate the possibility of the divalent metal cations
binding the enzyme at other sites other than the known metal coordination sites.
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Fig. 5.2. Restoration of catalytic activity of NPP7ExFLAG by divalent metals.
NPP7ExFLAG treated with EDTA for 16 hours was exposed to various divalent metal
cations and incubated at 4 oC for either 30 minutes (light grey bars) or 16 hours (dark
grey bars). The catalytic activity of the EDTA-metal-treated NPP7 was determined
using pNPPC as substrate.

5.3.3

Secondary structural analysis by CD spectroscopy
Circular dichroism (CD) spectroscopy was employed to study the effect of EDTA

chelation and divalent metal add back on the global secondary structure of
NPP7ExFLAG. Wavelength scan data from CD characterization of NPP7ExFLAG
(untreated control, EDTA treated for 16 hours and EDTA treated with metal ion add back
for 30 minutes) are shown in Fig. 5.3. No significant difference was noted in spectra
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obtained between 190-260 nm for any of the sample treatments indicating similar global
secondary structural compositions.
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Fig. 5.3. Secondary structural effects of EDTA and divalent metals.
NPP7ExFLAG treated with EDTA for 16 hours was then incubated for 30 minutes
with Ca2+(grey squares), Co2+ (white squares), Ni2 +(grey circles), Zn2+ (full black
circles) or just EDTA (white circles) before dilution and CD determination. A molar
ratio of 1:120:1E6 for Enzyme:EDTA:metal was used in each experiment.

The data obtained from these spectra was deconvoluted using default CDSSTR
settings on the DicroWeb server accessed at http://dicroweb.cryst.bbk.ac.uk. The percent
secondary structural compositions calculated for each sample are shown in Table 5.1. For
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the results to be meaningful, the CDSSTR algorithms have a maximum set error of 0.2.
The errors shown in Table 5.1 indicate the high confidence in the results obtained using
this algorithm.

Table 5.1. Secondary structural components of EDTA/metal-treated NPP7ExFLAG
% Secondary Structural Composition
Element

Untreated EDTA

2+

Ca

Co

2+

2+

2+

Ni

Zn

α-helix

31

31

31

32

31

30

β-sheet

12

11

14

12

13

20

Random coil

57

57

55

56

55

50

0.122

0.122

0.182

0.122

0.182

0.182

Max. Error

5.3.4 Effect of EDTA and divalent metals on thermal stability
Thermal scans were obtained at 222 nm for the same sample set used to
characterize global secondary structure. Data was collected at every degree between 20
and 100°C and was converted to a measure of the folded/unfolded fraction using the
equation (Folded fraction = ([θ] obs - [θ] den) / ([θ] nat -[θ]den) based on the work of Luthra et.
al. (6) where [θ]obs is the ellipticity at any temperature, [θ]den is the ellipticity at highest
temperature, and [θ] nat is the ellipticity at lowest temperature. Plots of the unfolded
fraction (1-folded fraction) versus temperature (°C) are shown in Fig. 5.4. The point at
which the protein is half unfolded is defined as T50. Table 5.2 is a compilation of the T 50
values obtained for each sample. The T 50 of the untreated protein was determined to be
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approximately 70oC. EDTA-treated NPP7ExFLAG had the highest T 50 value (75°C),
whereas the zinc-, nickel-, and cobalt-treated samples had T 50 values lower than that of
the untreated sample (60°C, 65°C and 68°C respectively). The T 50 of the protein
remained essentially unchanged with calcium treatment.
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Fig. 5.4. Effect of EDTA and divalent metals on the thermal stability of
NPP7ExFLAG. Thermal denaturation was studied at 222 nm. Samples shown were
pretreated with EDTA for 16 hours then treated with the divalent metals calcium (white
squares), cobalt (white circles), nickel (grey circles), zinc (black circles) or CD buffer
(grey squares). The temperature was steadily increased from 20 oC to100oC.
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Table 5.2. Melting temperatures of EDTA/metal-treated NPP7ExFLAG.
Sample treatment

Untreated

EDTA

Ca2+

Co2+

Ni2+

Zn2+

NPP7

70

75

71

68

65

60

5.4

Discussion
A requirement of divalent metal cations for catalytic activity is a general feature

of all NPP isoforms (1). Although the specific identity of the metal(s) present in each
individual NPP isoform has not yet been determined conclusively, several divalent metals
have previously been shown to restore the activity of NPP2, NPP6 and NPP7 (3, 7, 8).
Duan et al reported that NPP7 was significantly inhibited by Zn2+ and that the inhibitory
effect could be prevented by the addition of 2 mM EDTA (1, 5). It is important to note
that the experimental conditions under which these previous experiments were performed
were not detailed in the literature. In the current work we have established that, contrary
to these earlier reports, NPP7 is inhibited by EDTA at concentrations in the micromolar
range, although the inhibition takes time. Since the length of the ETDA treatment was
not included in the methods described by Duan and coworkers, we cannot be sure if this
is the root of the differences noted. We have also established that the catalytic activity of
this EDTA-treated enzyme is restored by the addition of cobalt, nickel and zinc,
suggesting that EDTA may have inhibited activity by either abstracting or chelating the
endogenous divalent metal cations making it unavailable for coordination within the
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enzyme’s active site. However our studies were not sufficient to distinguish between
these possibilities. All metals tested were added in excess at a 1:1 x 106 enzyme to metal
molar ratio but further work is ongoing where varying concentrations of divalent metal
cations coupled with dialysis to remove excess metal will be done before studying the
behavior of the enzyme. Our results showed that cobalt, nickel and zinc were able to
restore catalytic function after EDTA treatment. Despite these results, it remains
unknown if any of these three candidates is one or more of the divalent, active site metals
in endogenously expressed NPP7. Further experimentation using atomic absorption
spectroscopy is currently ongoing to establish the identity and stoichiometry of the metals
in the NPP7 active site.
In exploring the specific role of divalent metals in NPP7ExFLAG function, we
have established that the secondary structure of the enzyme does not change in the
presence or absence of the metals in its active site. Results from our CD experiments
established that the secondary structural composition of the enzyme remains the same
regardless of EDTA treatment and metal ion add back (Figure 5.3, Table 5.1). Since
catalytic function is effectively abolished with EDTA treatment over 16 hours
(presumably via endogenous metal removal) we conclude that the divalent metal cations
play a functional but not a structural role in this enzyme. Our work is not exhaustive in
the study of metal-binding by NPP7 because our experiments were designed with no
intermediate metal concentrations used. According to the proposed mechanism, NPP7
requires two divalent metal cations in the active site for activity and thus should not need
a large excess of metals for restoration of its activity. Future studies with lower metal
concentrations in addition to isothermal titration calorimetry experiments may shed light
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on whether the metals bind at sites other than the known coordination sites and if so are
there any effects associated with such interactions.
Interesting data were obtained for the influence of EDTA and divalent metal
cations on the thermal stability of NPP7ExFLAG. EDTA treated NPP7ExFLAG, which
exhibited significantly reduced catalytic activity, had a higher melting temperature than
the untreated control. These data suggest that EDTA treatment stabilized the enzyme
although the secondary structure composition was not altered. On the other hand,
addition of the divalent metal cations cobalt, nickel, and zinc (all shown to significant
restore NPP7 activity following EDTA treatment) led to a decrease in experimentally
determined T 50 of the protein. Calcium add back restored less activity than cobalt, nickel,
and zinc but the T 50 for this treatment was nearly unchanged from the control. These
results suggest that the cations may help provide molecular flexibility required for
function. This phenomenon requires further investigation as it is clear from the
wavelength spectra that none of these metals had a significant impact on the protein’s
secondary structure.
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CHAPTER 6

ACCOMPLISHMENTS AND CONCLUSIONS

Forty-one years have passed since the first paper was published detailing the
discovery, by Swedish scientist Ake Nilsson, of the protein that would eventually be
known as nucleotide pyrophosphatase/ phosphodiesterase (NPP) 7 (1). Duan and
colleagues purified the enzyme from human bile in 1997 (2). Their characterization
quickly excluded the enzyme from the sphingomyelinase family due to lack of functional
and structural similarities with known members including the acid and neutral
sphingomyelinases. Successive reports in 2002 and 2003 (3, 4) led to the association of
this Alk-SMase with the nucleotide pyrophosphatase/ phosphodiesterase (NPP) subfamily of alkaline phosphatase enzymes. More than thirty years after its discovery, the
complete cDNA sequence of Alk-SMase was successfully determined (Genbank
#AY20633) and the enzyme became the most recently identified member of the NPP
family and it was renamed NPP7 (3). NPP7 was shown to possess lysolipid
phosphodiesterase activity similar to the NPP2 and NPP6 isoforms (5) . NPP7 was
further classified as a lysophospholipase C (along with NPP6) due to its ability to cleave
phosphocholine from choline-containing lysolipid phosphodiesters substrates. To date,
NPP7 is the only known NPP isoform associated with anticancer effects which are
proposed to result from the hydrolysis of three endogenous substrates
lysophosphatidylcholine (LPC), platelet activating factor (PAF), and sphingomyelin (SM)
(6). Moreover, NPP7 has been associated with physiological processes such as
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cholesterol absorption and maturation of the intestinal tract as well as pathological
processes such as atherosclerosis and inflammatory bowel disease (7). Despite
considerable characterization of this enzyme, almost exclusively conducted by Duan and
coworkers, several unresolved questions remained about the structure and function of
NPP7. Our work has attempted to address questions of substrate specificity using novel
assay methods, with subsequent kinetic analysis. Questions concerning the role of
divalent metal cations and substrate specifying determinants were addressed using a
combination of CD spectroscopy, computational modeling, site-directed mutagenesis and
kinetic analysis.
The work to further characterize known and novel NPP7 substrates started with
application of a previously described Amplex Red-based assay to the analysis of NPP7
activity in a multi-well format. This method allowed for the kinetic characterization of
NPP7 activity using unmodified known and novel substrates. Using this approach we
identified two additional endogenous NPP7 substrates, lyso platelet activating factor
(lysoPAF) and sphingosylphosphorylcholine (SPC). In addition, one non-lipid substrate,
para-nitrophenylphosphocholine (pNPPC) was also identified and used with an adapted
absorbance assay to further examine NPP7 catalytic function. These methods are
important advances for NPP7 as multi-well assays were not described previously. As
such, cumbersome and expensive assays (such as radiolabeled substrates with TLC and
autoradiography) were previously the only choice.
The study of structure-activity relationships of NPP isoforms has been slowed due
a lack of physical structural data on NPP7. The only available crystal structure to use as
a template at the onset of this work was that of the bacterial Xac NPP (8). A homology
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model was generated based on this template that was used to analyze enzyme-substrate
interactions as a guide to site-directed mutagenesis. Our results identified F275 as an
essential residue for NPP7 recognition of all choline containing substrates. These efforts
are not exhaustive, but highlight further work needed in this area. With regard to
substrate identification, all the substrates tested here were choline phosphodiesters but a
survey of other lysophospholipids such as LPI, LPE, and LPG may also help understand
NPP7 function. In fact, since we found NPP7 to be less discriminating than NPP2 and
NPP6, it would be worthwhile testing additional analogs such as PE, PI, and PS as well.
Characterization of additional lipids will be helpful in understanding the role of F275
since its interaction point in the model complexes was with the choline group of all tested
substrates. More work is needed to completely understand substrate specifying
determinants of NPP7. The work described herein sets the stage for future experimental
site-directed mutagenesis of NPP7. A next logical step would be to examine the role of
specific sites by mutating them to their complementary residues in other NPP isoforms as
shown by Table 4.7. This approach would allow analysis of similarities and differences
in NPP substrate specificities and regioselectivies.
All NPP isoforms are known to be inactivated in the absence of divalent metal
cations. However, the identity of these metals remained unknown. Likewise, it was not
known whether these metals play only functional, or in addition, structural roles. Using a
combination of EDTA treatment, metal ion add back, functional analysis and circular
dichroism, we have established that the divalent metal cations play only functional and
not structural roles in NPP7. Experimental data showed that cobalt, nickel and zinc
restored activity of EDTA-treated NPP7 without significant effects on secondary
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structure. Future efforts can be focused on identification of the divalent metals present in
endogenous NPP7 by atomic absorption spectroscopy and characterization of metals such
as cobalt in the active site using electron paramagenetic resonance spectroscopy.
In conclusion, this work has addressed three significant areas associated with
human NPP7. The major legacy of this work has been the methodology generated that
will allow for future characterization of this important enzyme.
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APPENDIX
Human NPP7 (full length wild type)
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,
downstream: Not1)
Amino Acid
MRGPAVLLTV
GVKARYMTPA
NGSVPIWITA
AWFTEEDLDL
LIITSDHGMT
KDAHPKLHVY
DMKTIFRAVG
PDGRPTLLPK

Sequence
ALATLLAPGA
FVTMTSPCHF
QRQGLRAGSF
VTLYFGEPDS
TVDKRAGDLV
KKEAFPEAFH
PSFRAGLEVE
GRSALPPSSR

GAPVQSQGSQ
TLVTGKYIEN
FYPGGNVTYQ
TGHRYGPESP
EFHKFPNFTF
YANNPRVTPL
PFESVHVYEL
PLLVMGLLGT

NKLLLVSFDG
HGVVHNMYYN
GVAVTRSRKE
ERREMVRQVD
RDIEFELLDY
LMYSDLGYVI
MCRLLGIVPE
VILLSEVA

FRWNYDQDVD
TTSKVKLPYH
GIAHNYKNET
RTVGYLRESI
GPNGMLLPKE
HGRINVQFNN
ANDGHLATLL

TPNLDAMARD
ATLGIQRWWD
EWRANIDTVM
ARNHLTDRLN
GRLEKVYDAL
GEHGFDNKDM
PMLHTESALP

Nucleotide
atgagaggcc
ggagcaccgg
ttccgctgga
ggggtgaagg
accctggtca
accaccagca
aacggcagcg
ttctacccgg
ggcatcgcac
gcgtggttca
acgggccaca
cggaccgtgg
ctgatcatca
gaattccaca
ggaccaaacg
aaggacgccc
tacgccaaca
catgggagaa
gacatgaaga
ccctttgaga
gccaacgatg
cctgatggaa
cccctcctcg

Sequence
cggccgtcct
tacaaagtca
actacgacca
cacgctacat
ccggcaaata
aggtgaagct
tgcccatctg
gcgggaacgt
acaactacaa
cagaggagga
ggtacggccc
gctacctccg
catccgacca
agttccccaa
ggatgctgct
accccaagct
accccagggt
ttaacgtcca
ccatcttccg
gcgtccacgt
ggcacctagc
ggcctactct
tgatgggact

cctcactgtg
gggctcccag
ggacgtggac
gacccccgcc
tatcgagaac
gccctaccac
gatcacagcc
cacctaccaa
aaatgagacg
cctggatctg
cgagtccccg
ggagagcatc
cggcatgacg
cttcaccttc
ccctaaagaa
ccacgtctac
cacacccctg
gttcaacaat
cgctgtgggc
gtacgagctc
tactctgctg
cctgcccaag
gctggggacc

gctctggcca
aacaagctgc
acccccaacc
tttgtcacca
cacggggtgg
gccacgctgg
cagaggcagg
ggggtggctg
gagtggagag
gtcacactct
gagaggaggg
gcgcgcaacc
accgtggaca
cgggacatcg
gggaggctgg
aagaaggagg
ctgatgtaca
ggggagcacg
cctagcttca
atgtgccggc
cccatgctgc
ggaagatctg
gtgattcttc

cgctcctggc
tcctggtgtc
tggacgccat
tgaccagccc
ttcacaacat
gcatccagag
gcctgagggc
tgacgcggag
cgaacatcga
acttcgggga
agatggtgcg
acctcacaga
aacgggctgg
agtttgagct
agaaggtgta
cgttccccga
gcgaccttgg
gctttgacaa
gggcgggcct
tgctgggcat
acacagaatc
ctctcccgcc
tgtctgaggt

tcccggggcc
cttcgacggc
ggcccgagac
ctgccacttc
gtactacaac
gtggtgggac
tggctccttc
ccggaaagaa
cacagtgatg
gccggactcc
gcaggtggac
ccgcctcaac
cgacctggtt
cctggactac
cgatgccctc
ggccttccac
ctacgtcatc
caaggacatg
ggaggtggag
cgtgcccgag
tgctcttccg
cagcagcagg
cgca

Appendix 1.1. Human NPP7 (full length). Complete amino acid (top) and verified nucleotide
(bottom) sequences are shown. For reference the catalytic (T75) residue is highlighted in black.
The region highlighted in grey is cutoff to make the T415Ex construct.
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Human NPP7ExFLAG
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,
downstream: Not1)
Amino Acid
MRGPAVLLTV
GVKARYMTPA
NGSVPIWITA
AWFTEEDLDL
LIITSDHGMT
KDAHPKLHVY
DMKTIFRAVG
DDK

Sequence
ALATLLAPGA
FVTMTSPCHF
QRQGLRAGSF
VTLYFGEPDS
TVDKRAGDLV
KKEAFPEAFH
PSFRAGLEVE

GAPVQSQGSQ
TLVTGKYIEN
FYPGGNVTYQ
TGHRYGPESP
EFHKFPNFTF
YANNPRVTPL
PFESVHVYEL

NKLLLVSFDG
HGVVHNMYYN
GVAVTRSRKE
ERREMVRQVD
RDIEFELLDY
LMYSDLGYVI
MCRLLGIVPE

FRWNYDQDVD
TTSKVKLPYH
GIAHNYKNET
RTVGYLRESI
GPNGMLLPKE
HGRINVQFNN
ANDGHLATLL

TPNLDAMARD
ATLGIQRWWD
EWRANIDTVM
ARNHLTDRLN
GRLEKVYDAL
GEHGFDNKDM
PMLHTDYKDD

Nucleotide
atgagaggcc
ggagcaccgg
ttccgctgga
ggggtgaagg
accctggtca
accaccagca
aacggcagcg
ttctacccgg
ggcatcgcac
gcgtggttca
acgggccaca
cggaccgtgg
ctgatcatca
gaattccaca
ggaccaaacg
aaggacgccc
tacgccaaca
catgggagaa
gacatgaaga
ccctttgaga
gccaacgatg
gatgacaag

Sequence
cggccgtcct
tacaaagtca
actacgacca
cacgctacat
ccggcaaata
aggtgaagct
tgcccatctg
gcgggaacgt
acaactacaa
cagaggagga
ggtacggccc
gctacctccg
catccgacca
agttccccaa
ggatgctgct
accccaagct
accccagggt
ttaacgtcca
ccatcttccg
gcgtccacgt
ggcacctagc

cctcactgtg
gggctcccag
ggacgtggac
gacccccgcc
tatcgagaac
gccctaccac
gatcacagcc
cacctaccaa
aaatgagacg
cctggatctg
cgagtccccg
ggagagcatc
cggcatgacg
cttcaccttc
ccctaaagaa
ccacgtctac
cacacccctg
gttcaacaat
cgctgtgggc
gtacgagctc
tactctgctg

gctctggcca
aacaagctgc
acccccaacc
tttgtcacca
cacggggtgg
gccacgctgg
cagaggcagg
ggggtggctg
gagtggagag
gtcacactct
gagaggaggg
gcgcgcaacc
accgtggaca
cgggacatcg
gggaggctgg
aagaaggagg
ctgatgtaca
ggggagcacg
cctagcttca
atgtgccggc
cccatgctgc

cgctcctggc
tcctggtgtc
tggacgccat
tgaccagccc
ttcacaacat
gcatccagag
gcctgagggc
tgacgcggag
cgaacatcga
acttcgggga
agatggtgcg
acctcacaga
aacgggctgg
agtttgagct
agaaggtgta
cgttccccga
gcgaccttgg
gctttgacaa
gggcgggcct
tgctgggcat
acacagacta

tcccggggcc
cttcgacggc
ggcccgagac
ctgccacttc
gtactacaac
gtggtgggac
tggctccttc
ccggaaagaa
cacagtgatg
gccggactcc
gcaggtggac
ccgcctcaac
cgacctggtt
cctggactac
cgatgccctc
ggccttccac
ctacgtcatc
caaggacatg
ggaggtggag
cgtgcccgag
caaggacgac

Appendix 1.2. Human NPP7ExFLAG. Complete amino acid (top) and verified nucleotide
(bottom) sequences are shown. For reference the catalytic (T75) residue is highlighted in black
and the FLAG affinity tag is highlighted in grey.
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Human NPP7ExFLAG-F80A
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,
downstream: Not1)
Amino acid
MRGPAVLLTV
GVKARYMTPA
NGSVPIWITA
AWFTEEDLDL
LIITSDHGMT
KDAHPKLHVY
DMKTIFRAVG
DDK

Sequence
ALATLLAPGA
FVTMTSPCHA
QRQGLRAGSF
VTLYFGEPDS
TVDKRAGDLV
KKEAFPEAFH
PSFRAGLEVE

GAPVQSQGSQ
TLVTGKYIEN
FYPGGNVTYQ
TGHRYGPESP
EFHKFPNFTF
YANNPRVTPL
PFESVHVYEL

NKLLLVSFDG
HGVVHNMYYN
GVAVTRSRKE
ERREMVRQVD
RDIEFELLDY
LMYSDLGYVI
MCRLLGIVPE

FRWNYDQDVD
TTSKVKLPYH
GIAHNYKNET
RTVGYLRESI
GPNGMLLPKE
HGRINVQFNN
ANDGHLATLL

TPNLDAMARD
ATLGIQRWWD
EWRANIDTVM
ARNHLTDRLN
GRLEKVYDAL
GEHGFDNKDM
PMLHTDYKDD

Nucleotide
atgagaggcc
ggagcaccgg
ttccgctgga
ggggtgaagg
accctggtca
accaccagca
aacggcagcg
ttctacccgg
ggcatcgcac
gcgtggttca
acgggccaca
cggaccgtgg
ctgatcatca
gaattccaca
ggaccaaacg
aaggacgccc
tacgccaaca
catgggagaa
gacatgaaga
ccctttgaga
gccaacgatg
gatgacaag

Sequence
cggccgtcct
tacaaagtca
actacgacca
cacgctacat
ccggcaaata
aggtgaagct
tgcccatctg
gcgggaacgt
acaactacaa
cagaggagga
ggtacggccc
gctacctccg
catccgacca
agttccccaa
ggatgctgct
accccaagct
accccagggt
ttaacgtcca
ccatcttccg
gcgtccacgt
ggcacctagc

cctcactgtg
gggctcccag
ggacgtggac
gacccccgcc
tatcgagaac
gccctaccac
gatcacagcc
cacctaccaa
aaatgagacg
cctggatctg
cgagtccccg
ggagagcatc
cggcatgacg
cttcaccttc
ccctaaagaa
ccacgtctac
cacacccctg
gttcaacaat
cgctgtgggc
gtacgagctc
tactctgctg

gctctggcca
aacaagctgc
acccccaacc
tttgtcacca
cacggggtgg
gccacgctgg
cagaggcagg
ggggtggctg
gagtggagag
gtcacactct
gagaggaggg
gcgcgcaacc
accgtggaca
cgggacatcg
gggaggctgg
aagaaggagg
ctgatgtaca
ggggagcacg
cctagcttca
atgtgccggc
cccatgctgc

cgctcctggc
tcctggtgtc
tggacgccat
tgaccagccc
ttcacaacat
gcatccagag
gcctgagggc
tgacgcggag
cgaacatcga
acttcgggga
agatggtgcg
acctcacaga
aacgggctgg
agtttgagct
agaaggtgta
cgttccccga
gcgaccttgg
gctttgacaa
gggcgggcct
tgctgggcat
acacagacta

tcccggggcc
cttcgacggc
ggcccgagac
ctgccacgcc
gtactacaac
gtggtgggac
tggctccttc
ccggaaagaa
cacagtgatg
gccggactcc
gcaggtggac
ccgcctcaac
cgacctggtt
cctggactac
cgatgccctc
ggccttccac
ctacgtcatc
caaggacatg
ggaggtggag
cgtgcccgag
caaggacgac

Appendix 1.3. Human NPP7ExFLAG-F80A. Complete amino acid (top) and verified
nucleotide (bottom) sequences are shown. For reference the catalytic (T75) residue is highlighted
in black and the FLAG affinity tag is highlighted in grey. The mutation site is highlighted in
blue.
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Human NPP7ExFLAG-L107F
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,
downstream: Not1)
Amino acid
MRGPAVLLTV
GVKARYMTPA
NGSVPIWITA
AWFTEEDLDL
LIITSDHGMT
KDAHPKLHVY
DMKTIFRAVG
DDK

Sequence
ALATLLAPGA
FVTMTSPCHF
QRQGLRAGSF
VTLYFGEPDS
TVDKRAGDLV
KKEAFPEAFH
PSFRAGLEVE

GAPVQSQGSQ
TLVTGKYIEN
FYPGGNVTYQ
TGHRYGPESP
EFHKFPNFTF
YANNPRVTPL
PFESVHVYEL

NKLLLVSFDG
HGVVHNMYYN
GVAVTRSRKE
ERREMVRQVD
RDIEFELLDY
LMYSDLGYVI
MCRLLGIVPE

FRWNYDQDVD
TTSKVKFPYH
GIAHNYKNET
RTVGYLRESI
GPNGMLLPKE
HGRINVQFNN
ANDGHLATLL

TPNLDAMARD
ATLGIQRWWD
EWRANIDTVM
ARNHLTDRLN
GRLEKVYDAL
GEHGFDNKDM
PMLHTDYKDD

Nucleotide
atgagaggcc
ggagcaccgg
ttccgctgga
ggggtgaagg
accctggtca
accaccagca
aacggcagcg
ttctacccgg
ggcatcgcac
gcgtggttca
acgggccaca
cggaccgtgg
ctgatcatca
gaattccaca
ggaccaaacg
aaggacgccc
tacgccaaca
catgggagaa
gacatgaaga
ccctttgaga
gccaacgatg
gatgacaag

Sequence
cggccgtcct
tacaaagtca
actacgacca
cacgctacat
ccggcaaata
aggtgaagtt
tgcccatctg
gcgggaacgt
acaactacaa
cagaggagga
ggtacggccc
gctacctccg
catccgacca
agttccccaa
ggatgctgct
accccaagct
accccagggt
ttaacgtcca
ccatcttccg
gcgtccacgt
ggcacctagc

cctcactgtg
gggctcccag
ggacgtggac
gacccccgcc
tatcgagaac
cccctaccac
gatcacagcc
cacctaccaa
aaatgagacg
cctggatctg
cgagtccccg
ggagagcatc
cggcatgacg
cttcaccttc
ccctaaagaa
ccacgtctac
cacacccctg
gttcaacaat
cgctgtgggc
gtacgagctc
tactctgctg

gctctggcca
aacaagctgc
acccccaacc
tttgtcacca
cacggggtgg
gccacgctgg
cagaggcagg
ggggtggctg
gagtggagag
gtcacactct
gagaggaggg
gcgcgcaacc
accgtggaca
cgggacatcg
gggaggctgg
aagaaggagg
ctgatgtaca
ggggagcacg
cctagcttca
atgtgccggc
cccatgctgc

cgctcctggc
tcctggtgtc
tggacgccat
tgaccagccc
ttcacaacat
gcatccagag
gcctgagggc
tgacgcggag
cgaacatcga
acttcgggga
agatggtgcg
acctcacaga
aacgggctgg
agtttgagct
agaaggtgta
cgttccccga
gcgaccttgg
gctttgacaa
gggcgggcct
tgctgggcat
acacagacta

tcccggggcc
cttcgacggc
ggcccgagac
ctgccacttc
gtactacaac
gtggtgggac
tggctccttc
ccggaaagaa
cacagtgatg
gccggactcc
gcaggtggac
ccgcctcaac
cgacctggtt
cctggactac
cgatgccctc
ggccttccac
ctacgtcatc
caaggacatg
ggaggtggag
cgtgcccgag
caaggacgac

Appendix 1.4. Human NPP7ExFLAG- L107F. Complete amino acid (top) and verified
nucleotide (bottom) sequences are shown. For reference the catalytic (T75) residue is highlighted
in black and the FLAG affinity tag is highlighted in grey. The mutation site is highlighted in
blue.
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Human NPP7ExFLAG-Y142A
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,
downstream: Not1)
Amino acid
MRGPAVLLTV
GVKARYMTPA
NGSVPIWITA
AWFTEEDLDL
LIITSDHGMT
KDAHPKLHVY
DMKTIFRAVG
DDK

Sequence
ALATLLAPGA
FVTMTSPCHF
QRQGLRAGSF
VTLYFGEPDS
TVDKRAGDLV
KKEAFPEAFH
PSFRAGLEVE

GAPVQSQGSQ
TLVTGKYIEN
FAPGGNVTYQ
TGHRYGPESP
EFHKFPNFTF
YANNPRVTPL
PFESVHVYEL

NKLLLVSFDG
HGVVHNMYYN
GVAVTRSRKE
ERREMVRQVD
RDIEFELLDY
LMYSDLGYVI
MCRLLGIVPE

FRWNYDQDVD
TTSKVKLPYH
GIAHNYKNET
RTVGYLRESI
GPNGMLLPKE
HGRINVQFNN
ANDGHLATLL

TPNLDAMARD
ATLGIQRWWD
EWRANIDTVM
ARNHLTDRLN
GRLEKVYDAL
GEHGFDNKDM
PMLHTDYKDD

Nucleotide
atgagaggcc
ggagcaccgg
ttccgctgga
ggggtgaagg
accctggtca
accaccagca
aacggcagcg
ttcgccccgg
ggcatcgcac
gcgtggttca
acgggccaca
cggaccgtgg
ctgatcatca
gaattccaca
ggaccaaacg
aaggacgccc
tacgccaaca
catgggagaa
gacatgaaga
ccctttgaga
gccaacgatg
gatgacaag

Sequence
cggccgtcct
tacaaagtca
actacgacca
cacgctacat
ccggcaaata
aggtgaagct
tgcccatctg
gcgggaacgt
acaactacaa
cagaggagga
ggtacggccc
gctacctccg
catccgacca
agttccccaa
ggatgctgct
accccaagct
accccagggt
ttaacgtcca
ccatcttccg
gcgtccacgt
ggcacctagc

cctcactgtg
gggctcccag
ggacgtggac
gacccccgcc
tatcgagaac
gccctaccac
gatcacagcc
cacctaccaa
aaatgagacg
cctggatctg
cgagtccccg
ggagagcatc
cggcatgacg
cttcaccttc
ccctaaagaa
ccacgtctac
cacacccctg
gttcaacaat
cgctgtgggc
gtacgagctc
tactctgctg

gctctggcca
aacaagctgc
acccccaacc
tttgtcacca
cacggggtgg
gccacgctgg
cagaggcagg
ggggtggctg
gagtggagag
gtcacactct
gagaggaggg
gcgcgcaacc
accgtggaca
cgggacatcg
gggaggctgg
aagaaggagg
ctgatgtaca
ggggagcacg
cctagcttca
atgtgccggc
cccatgctgc

cgctcctggc
tcctggtgtc
tggacgccat
tgaccagccc
ttcacaacat
gcatccagag
gcctgagggc
tgacgcggag
cgaacatcga
acttcgggga
agatggtgcg
acctcacaga
aacgggctgg
agtttgagct
agaaggtgta
cgttccccga
gcgaccttgg
gctttgacaa
gggcgggcct
tgctgggcat
acacagacta

tcccggggcc
cttcgacggc
ggcccgagac
ctgccacttc
gtactacaac
gtggtgggac
tggctccttc
ccggaaagaa
cacagtgatg
gccggactcc
gcaggtggac
ccgcctcaac
cgacctggtt
cctggactac
cgatgccctc
ggccttccac
ctacgtcatc
caaggacatg
ggaggtggag
cgtgcccgag
caaggacgac

Appendix 1.5. Human NPP7ExFLAG- Y142A. Complete amino acid (top) and verified
nucleotide (bottom) sequences are shown. For reference the catalytic (T75) residue is highlighted
in black and the FLAG affinity tag is highlighted in grey. The mutation site is highlighted in
blue.
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Human NPP7ExFLAG-Y166A
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,
downstream: Not1)
Amino acid
MRGPAVLLTV
GVKARYMTPA
NGSVPIWITA
AWFTEEDLDL
LIITSDHGMT
KDAHPKLHVY
DMKTIFRAVG
DDK

Sequence
ALATLLAPGA
FVTMTSPCHF
QRQGLRAGSF
VTLYFGEPDS
TVDKRAGDLV
KKEAFPEAFH
PSFRAGLEVE

GAPVQSQGSQ
TLVTGKYIEN
FYPGGNVTYQ
TGHRYGPESP
EFHKFPNFTF
YANNPRVTPL
PFESVHVYEL

NKLLLVSFDG
HGVVHNMYYN
GVAVTRSRKE
ERREMVRQVD
RDIEFELLDY
LMYSDLGYVI
MCRLLGIVPE

FRWNYDQDVD
TTSKVKLPYH
GIAHNAKNET
RTVGYLRESI
GPNGMLLPKE
HGRINVQFNN
ANDGHLATLL

TPNLDAMARD
ATLGIQRWWD
EWRANIDTVM
ARNHLTDRLN
GRLEKVYDAL
GEHGFDNKDM
PMLHTDYKDD

Nucleotide
atgagaggcc
ggagcaccgg
ttccgctgga
ggggtgaagg
accctggtca
accaccagca
aacggcagcg
ttctacccgg
ggcatcgcac
gcgtggttca
acgggccaca
cggaccgtgg
ctgatcatca
gaattccaca
ggaccaaacg
aaggacgccc
tacgccaaca
catgggagaa
gacatgaaga
ccctttgaga
gccaacgatg
gatgacaag

Sequence
cggccgtcct
tacaaagtca
actacgacca
cacgctacat
ccggcaaata
aggtgaagct
tgcccatctg
gcgggaacgt
acaacgccaa
cagaggagga
ggtacggccc
gctacctccg
catccgacca
agttccccaa
ggatgctgct
accccaagct
accccagggt
ttaacgtcca
ccatcttccg
gcgtccacgt
ggcacctagc

cctcactgtg
gggctcccag
ggacgtggac
gacccccgcc
tatcgagaac
gccctaccac
gatcacagcc
cacctaccaa
aaatgagacg
cctggatctg
cgagtccccg
ggagagcatc
cggcatgacg
cttcaccttc
ccctaaagaa
ccacgtctac
cacacccctg
gttcaacaat
cgctgtgggc
gtacgagctc
tactctgctg

gctctggcca
aacaagctgc
acccccaacc
tttgtcacca
cacggggtgg
gccacgctgg
cagaggcagg
ggggtggctg
gagtggagag
gtcacactct
gagaggaggg
gcgcgcaacc
accgtggaca
cgggacatcg
gggaggctgg
aagaaggagg
ctgatgtaca
ggggagcacg
cctagcttca
atgtgccggc
cccatgctgc

cgctcctggc
tcctggtgtc
tggacgccat
tgaccagccc
ttcacaacat
gcatccagag
gcctgagggc
tgacgcggag
cgaacatcga
acttcgggga
agatggtgcg
acctcacaga
aacgggctgg
agtttgagct
agaaggtgta
cgttccccga
gcgaccttgg
gctttgacaa
gggcgggcct
tgctgggcat
acacagacta

tcccggggcc
cttcgacggc
ggcccgagac
ctgccacttc
gtactacaac
gtggtgggac
tggctccttc
ccggaaagaa
cacagtgatg
gccggactcc
gcaggtggac
ccgcctcaac
cgacctggtt
cctggactac
cgatgccctc
ggccttccac
ctacgtcatc
caaggacatg
ggaggtggag
cgtgcccgag
caaggacgac

Appendix 1.6. Human NPP7ExFLAG- Y166A. Complete amino acid (top) and verified
nucleotide (bottom) sequences are shown. For reference the catalytic (T75) residue is highlighted
in black and the FLAG affinity tag is highlighted in grey. The mutation site is highlighted in
blue.
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Human NPP7ExFLAG-E169A
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,
downstream: Not1)
Amino acid
MRGPAVLLTV
GVKARYMTPA
NGSVPIWITA
AWFTEEDLDL
LIITSDHGMT
KDAHPKLHVY
DMKTIFRAVG
DDK

Sequence
ALATLLAPGA
FVTMTSPCHF
QRQGLRAGSF
VTLYFGEPDS
TVDKRAGDLV
KKEAFPEAFH
PSFRAGLEVE

GAPVQSQGSQ
TLVTGKYIEN
FYPGGNVTYQ
TGHRYGPESP
EFHKFPNFTF
YANNPRVTPL
PFESVHVYEL

NKLLLVSFDG
HGVVHNMYYN
GVAVTRSRKE
ERREMVRQVD
RDIEFELLDY
LMYSDLGYVI
MCRLLGIVPE

FRWNYDQDVD
TTSKVKLPYH
GIAHNYKNAT
RTVGYLRESI
GPNGMLLPKE
HGRINVQFNN
ANDGHLATLL

TPNLDAMARD
ATLGIQRWWD
EWRANIDTVM
ARNHLTDRLN
GRLEKVYDAL
GEHGFDNKDM
PMLHTDYKDD

Nucleotide
atgagaggcc
ggagcaccgg
ttccgctgga
ggggtgaagg
accctggtca
accaccagca
aacggcagcg
ttctacccgg
ggcatcgcac
gcgtggttca
acgggccaca
cggaccgtgg
ctgatcatca
gaattccaca
ggaccaaacg
aaggacgccc
tacgccaaca
catgggagaa
gacatgaaga
ccctttgaga
gccaacgatg
gatgacaag

Sequence
cggccgtcct
tacaaagtca
actacgacca
cacgctacat
ccggcaaata
aggtgaagct
tgcccatctg
gcgggaacgt
acaactacaa
cagaggagga
ggtacggccc
gctacctccg
catccgacca
agttccccaa
ggatgctgct
accccaagct
accccagggt
ttaacgtcca
ccatcttccg
gcgtccacgt
ggcacctagc

cctcactgtg
gggctcccag
ggacgtggac
gacccccgcc
tatcgagaac
gccctaccac
gatcacagcc
cacctaccaa
aaatgcgacg
cctggatctg
cgagtccccg
ggagagcatc
cggcatgacg
cttcaccttc
ccctaaagaa
ccacgtctac
cacacccctg
gttcaacaat
cgctgtgggc
gtacgagctc
tactctgctg

gctctggcca
aacaagctgc
acccccaacc
tttgtcacca
cacggggtgg
gccacgctgg
cagaggcagg
ggggtggctg
gagtggagag
gtcacactct
gagaggaggg
gcgcgcaacc
accgtggaca
cgggacatcg
gggaggctgg
aagaaggagg
ctgatgtaca
ggggagcacg
cctagcttca
atgtgccggc
cccatgctgc

cgctcctggc
tcctggtgtc
tggacgccat
tgaccagccc
ttcacaacat
gcatccagag
gcctgagggc
tgacgcggag
cgaacatcga
acttcgggga
agatggtgcg
acctcacaga
aacgggctgg
agtttgagct
agaaggtgta
cgttccccga
gcgaccttgg
gctttgacaa
gggcgggcct
tgctgggcat
acacagacta

tcccggggcc
cttcgacggc
ggcccgagac
ctgccacttc
gtactacaac
gtggtgggac
tggctccttc
ccggaaagaa
cacagtgatg
gccggactcc
gcaggtggac
ccgcctcaac
cgacctggtt
cctggactac
cgatgccctc
ggccttccac
ctacgtcatc
caaggacatg
ggaggtggag
cgtgcccgag
caaggacgac

Appendix 1.7. Human NPP7ExFLAG- E169A. Complete amino acid (top) and verified
nucleotide (bottom) sequences are shown. For reference the catalytic (T75) residue is highlighted
in black and the FLAG affinity tag is highlighted in grey. The mutation site is highlighted in
blue.
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Human NPP7ExFLAG-E169Q
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,
downstream: Not1)
Amino acid
MRGPAVLLTV
GVKARYMTPA
NGSVPIWITA
AWFTEEDLDL
LIITSDHGMT
KDAHPKLHVY
DMKTIFRAVG
DDK

Sequence
ALATLLAPGA
FVTMTSPCHF
QRQGLRAGSF
VTLYFGEPDS
TVDKRAGDLV
KKEAFPEAFH
PSFRAGLEVE

GAPVQSQGSQ
TLVTGKYIEN
FYPGGNVTYQ
TGHRYGPESP
EFHKFPNFTF
YANNPRVTPL
PFESVHVYEL

NKLLLVSFDG
HGVVHNMYYN
GVAVTRSRKE
ERREMVRQVD
RDIEFELLDY
LMYSDLGYVI
MCRLLGIVPE

FRWNYDQDVD
TTSKVKLPYH
GIAHNYKNQT
RTVGYLRESI
GPNGMLLPKE
HGRINVQFNN
ANDGHLATLL

TPNLDAMARD
ATLGIQRWWD
EWRANIDTVM
ARNHLTDRLN
GRLEKVYDAL
GEHGFDNKDM
PMLHTDYKDD

Nucleotide
atgagaggcc
ggagcaccgg
ttccgctgga
ggggtgaagg
accctggtca
accaccagca
aacggcagcg
ttctacccgg
ggcatcgcac
gcgtggttca
acgggccaca
cggaccgtgg
ctgatcatca
gaattccaca
ggaccaaacg
aaggacgccc
tacgccaaca
catgggagaa
gacatgaaga
ccctttgaga
gccaacgatg
gatgacaag

Sequence
cggccgtcct
tacaaagtca
actacgacca
cacgctacat
ccggcaaata
aggtgaagct
tgcccatctg
gcgggaacgt
acaactacaa
cagaggagga
ggtacggccc
gctacctccg
catccgacca
agttccccaa
ggatgctgct
accccaagct
accccagggt
ttaacgtcca
ccatcttccg
gcgtccacgt
ggcacctagc

cctcactgtg
gggctcccag
ggacgtggac
gacccccgcc
tatcgagaac
gccctaccac
gatcacagcc
cacctaccaa
aaatcagacg
cctggatctg
cgagtccccg
ggagagcatc
cggcatgacg
cttcaccttc
ccctaaagaa
ccacgtctac
cacacccctg
gttcaacaat
cgctgtgggc
gtacgagctc
tactctgctg

gctctggcca
aacaagctgc
acccccaacc
tttgtcacca
cacggggtgg
gccacgctgg
cagaggcagg
ggggtggctg
gagtggagag
gtcacactct
gagaggaggg
gcgcgcaacc
accgtggaca
cgggacatcg
gggaggctgg
aagaaggagg
ctgatgtaca
ggggagcacg
cctagcttca
atgtgccggc
cccatgctgc

cgctcctggc
tcctggtgtc
tggacgccat
tgaccagccc
ttcacaacat
gcatccagag
gcctgagggc
tgacgcggag
cgaacatcga
acttcgggga
agatggtgcg
acctcacaga
aacgggctgg
agtttgagct
agaaggtgta
cgttccccga
gcgaccttgg
gctttgacaa
gggcgggcct
tgctgggcat
acacagacta

tcccggggcc
cttcgacggc
ggcccgagac
ctgccacttc
gtactacaac
gtggtgggac
tggctccttc
ccggaaagaa
cacagtgatg
gccggactcc
gcaggtggac
ccgcctcaac
cgacctggtt
cctggactac
cgatgccctc
ggccttccac
ctacgtcatc
caaggacatg
ggaggtggag
cgtgcccgag
caaggacgac

Appendix 1.8. Human NPP7ExFLAG- E169Q. Complete amino acid (top) and verified
nucleotide (bottom) sequences are shown. For reference the catalytic (T75) residue is highlighted
in black and the FLAG affinity tag is highlighted in grey. The mutation site is highlighted in
blue.
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Human NPP7ExFLAG-F275A
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,
downstream: Not1)
Amino acid
MRGPAVLLTV
GVKARYMTPA
NGSVPIWITA
AWFTEEDLDL
LIITSDHGMT
KDAHPKLHVY
DMKTIFRAVG
DDK

Sequence
ALATLLAPGA
FVTMTSPCHF
QRQGLRAGSF
VTLYFGEPDS
TVDKRAGDLV
KKEAFPEAFH
PSFRAGLEVE

GAPVQSQGSQ
TLVTGKYIEN
FYPGGNVTYQ
TGHRYGPESP
EFHKFPNFTF
YANNPRVTPL
PFESVHVYEL

NKLLLVSFDG
HGVVHNMYYN
GVAVTRSRKE
ERREMVRQVD
RDIEFELLDY
LMYSDLGYVI
MCRLLGIVPE

FRWNYDQDVD
TTSKVKLPYH
GIAHNYKNET
RTVGYLRESI
GPNGMLLPKE
HGRINVQFNN
ANDGHLATLL

TPNLDAMARD
ATLGIQRWWD
EWRANIDTVM
ARNHLTDRLN
GRLEKVYDAL
GEHGFDNKDM
PMLHTDYKDD

Nucleotide
atgagaggcc
ggagcaccgg
ttccgctgga
ggggtgaagg
accctggtca
accaccagca
aacggcagcg
ttctacccgg
ggcatcgcac
gcgtggttca
acgggccaca
cggaccgtgg
ctgatcatca
gaattccaca
ggaccaaacg
aaggacgccc
tacgccaaca
catgggagaa
gacatgaaga
ccctttgaga
gccaacgatg
gatgacaag

Sequence
cggccgtcct
tacaaagtca
actacgacca
cacgctacat
ccggcaaata
aggtgaagct
tgcccatctg
gcgggaacgt
acaactacaa
cagaggagga
ggtacggccc
gctacctccg
catccgacca
agttccccaa
ggatgctgct
accccaagct
accccagggt
ttaacgtcca
ccatcttccg
gcgtccacgt
ggcacctagc

cctcactgtg
gggctcccag
ggacgtggac
gacccccgcc
tatcgagaac
gccctaccac
gatcacagcc
cacctaccaa
aaatgagacg
cctggatctg
cgagtccccg
ggagagcatc
cggcatgacg
cttcaccttc
ccctaaagaa
ccacgtctac
cacacccctg
gttcaacaat
cgctgtgggc
gtacgagctc
tactctgctg

gctctggcca
aacaagctgc
acccccaacc
tttgtcacca
cacggggtgg
gccacgctgg
cagaggcagg
ggggtggctg
gagtggagag
gtcacactct
gagaggaggg
gcgcgcaacc
accgtggaca
cgggacatcg
gggaggctgg
aagaaggagg
ctgatgtaca
ggggagcacg
cctagcttca
atgtgccggc
cccatgctgc

cgctcctggc
tcctggtgtc
tggacgccat
tgaccagccc
ttcacaacat
gcatccagag
gcctgagggc
tgacgcggag
cgaacatcga
acttcgggga
agatggtgcg
acctcacaga
aacgggctgg
aggctgagct
agaaggtgta
cgttccccga
gcgaccttgg
gctttgacaa
gggcgggcct
tgctgggcat
acacagacta

tcccggggcc
cttcgacggc
ggcccgagac
ctgccacttc
gtactacaac
gtggtgggac
tggctccttc
ccggaaagaa
cacagtgatg
gccggactcc
gcaggtggac
ccgcctcaac
cgacctggtt
cctggactac
cgatgccctc
ggccttccac
ctacgtcatc
caaggacatg
ggaggtggag
cgtgcccgag
caaggacgac

Appendix 1.9. Human NPP7ExFLAG- F275A. Complete amino acid (top) and verified
nucleotide (bottom) sequences are shown. For reference the catalytic (T75) residue is highlighted
in black and the FLAG affinity tag is highlighted in grey. The mutation site is highlighted in
blue.
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